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ABSTRACT 
 
This study aims to investigate the effect of the manufacturing process cryomilling on the 
antibacterial effectiveness of a novel antibacterial agent ZnS. ZnS nanoparticles are getting 
attention for their potential antibacterial properties due to the fact that release of Zn ions has 
demonstrated promising preliminary effects when applied on skin wounds. Particle size is 
essential to achieve bacteria inhibition and elimination since it has been shown that antibacterial 
activity can be increased with reduced particle size, which results in higher surface to volume 
ratio. In this study, ZnS nanoparticles were synthesized using one-pot colloidal synthesis as well 
as using biological Sulfate Reducing Bacteria synthesis under anaerobic environment with 
proper media. Both types of ZnS were further processed through cryomilling after synthesis to 
reduce the particle size. Scanning electron microscopy and X-ray diffraction techniques were 
used to characterize the morphology and crystallinity of the ZnS nanoparticles. To assess 
bacteria inhibition and elimination, in vitro ZOI studies consisting of inoculating cellulose disks 
on agar plates with Staphylococcus aureus (S. aureus) followed by incubation for 24 hours were 
performed. In vitro biofilm models consisting of inoculating cellulose disks on well-developed S. 
aureus biofilm on agar plates followed by 24-hour incubation were also conducted. CLSM was 
employed to qualitatively observe the antibacterial effectiveness; statistical analysis was also 
performed to quantitatively study the effectiveness of ZnS as antibacterial agents by counting the 
residual CFU left on the cellular disks. Results showed that the ZnS nanoparticles possess very 
good antibacterial properties against S. aureus, and incorporating cryomilling enhances ZnS 
antibacterial effectiveness.  
xii 
 
THESIS ORGANIZATION 
 
In this thesis, Chapter 1 presents the general introduction and information of this 
research. Chapter 2 gives a thorough literature review of the current studies on related fields 
including wound healing process, antibacterial agents on burn wound healing and common 
manufacturing processes for synthesis of ZnS, which provides the knowledge basis for the 
development of this research. Chapter 3 describes a pilot evaluation of the effectiveness of 
chemically synthesized ZnS as an antibacterial agent, which provides the rationale for choosing 
the alternative method of manufacturing for ZnS. Chapter 4 illustrates the detailed experiment 
design and implementation, together with results analysis and conclusions about the study of ZnS 
antibacterial effectiveness for healing burn wounds. Chapter 5 provides the general conclusions 
and the future research direction of this project. 
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CHAPTER 1. 
GENERAL INTRODUCTION 
 
Burn wounds are one of the most commonly encountered damages to the skin, due to the 
thermal damage from burn, the immune systems surrounding the wounds can be destroyed, thus 
causing a higher possibility of bacterial infection than other wounds [1-3]. There are many 
different types of bacteria that can colonize on the burn wound site, however, S. aureus and P. 
aeruginosa are the major infections sources [4]. As delay in bacteria clearance on the wound site 
can result in delay of wound healing or even transition from acute wound to chronic wound [5], 
many different types of antibacterial agents were applied in order to treat burn wound and reduce 
the time frame of wound healing. Other than infection itself, the formation of biofilm poses an 
even more serious problem as biofilm is even harder for antibiotics to completely eradicate than 
common bacterial infection [6]. 
Antibiotics used to play a major role for burn infection treatment, however, over the past 
decades, the emerging problem of antibiotic resistance has become a serious issue due to the 
overuse of antibiotics [7, 8]. In recent years, metallic compounds are starting to gain popularity 
in terms of their broad spectrum of antibacterial effectiveness, among them, Ag and ZnO are two 
extensively studied examples. However, studies have shown that bacteria are gaining resistance 
against Ag [9, 10], thus new drugs are always in need in order to counter the bacteria mutation. 
ZnS is a novel antibacterial substance that recently started to attract attention, however, available 
studies basically utilized environmentally unfriendly chemical synthesis to produce ZnS [11], 
and limited to very few types of bacteria, which did not include one of the most common burn 
wound infection source S. aureus [12-14]. As an alternative, we used SRB to biologically 
synthesize ZnS to test its effectiveness on S. aureus. 
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An important factor that contributes to the antibacterial properties is the particle size of 
the material. Smaller sized particles have larger surface to volume ration, resulting in larger 
surface in direct contact with the exterior environment under same amount of antibacterial agents, 
thus it is expected that the smaller the particle size of the drugs, the higher antibacterial 
properties they will possess [15]. In order to test the effect of size reduction on antibacterial 
properties, cryomilling was used as a manufacturing process to reduce the particle size, and the 
ZnS with two different particle sizes were used to compare the antibacterial properties. 
This study aims at investigating the antibacterial effectiveness of ZnS on S. aureus 
infection. In order to compare the effectiveness of cryomilling as well as different manufacturing 
methods for ZnS synthesis, four types of ZnS were synthesized. The Comp A was the original 
ZnS produced using SRB as described in previous study [16], and Comp B was produced using 
cryomilling as a manufacturing process over the original biosynthesized ZnS Comp A. In 
conjunction with this study, the conventional chemical synthesis was also employed to produce 
ZnS, and the antibacterial effectiveness was evaluated accordingly. Comp C was the chemically 
synthesized ZnS particles, and Comp D was the chemical synthesized ZnS which was further 
processed using cryomilling. Evaluation results showed that, although cryomilled Comp D 
showed very good antibacterial properties, the chemical synthesized ZnS Comp C did not show 
antibacterial properties. Based on the evaluation results and the other drawbacks related to 
production such as environmental hazard and high temperature requirement, we chose 
biosynthesis as the source for ZnS in this study. 
The characterization methods used included SEM analysis and XRD analysis. The results 
showed that the produced particles are ZnS with sphalerite crystal structures, and the particle size 
has been dramatically decreased by cryomilling. 
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In order to test the antibacterial effectiveness, several tests were conducted including ZOI 
assay, followed by in vitro biofilm study. In biofilm study, the residual biofilm after being 
treated with ZnS was first observed using CLSM to qualitatively observe biofilms development, 
and later it was quantitatively counted to determine the effectiveness of the ZnS as antibacterial 
agent. The results showed that the Comp A and Comp B ZnS are both effective against S. aureus, 
and reached the desired level of effectiveness. In the meantime cryomilling as a post-synthesis 
process has played a positive role in increasing the antibacterial effectiveness of ZnS. 
 
  
4 
 
CHAPTER 2. 
LITERATURE REVIEW 
 
This review of literature is divided into 8 parts: 1) Types of wounds, 2) Wound healing 
process, 3) Bacteria and impact on wound healing, 4) Antibacterial mechanisms, 5) Topical 
antibacterial drugs for burn wound treatment, 6) Synthesis of ZnS, 7) Cryomilling, 8) Summary 
of literature. 
 
2.1 Types of Wounds 
 
Wounds are common around the world, and there are many different ways of 
categorizing wounds. Sections 2.1.1 to 2.1.4 illustrate 4 major criteria by which the wounds can 
be classified. As the major type of wound that this study focused on, burn wounds are explained 
specifically in Section. 2.1.5. 
 
2.1.1 Causes of Wounds 
 
Based on the causes of the wounds, they can be categorized into traumatic, iatrogenic and 
burn wounds. Traumatic wounds are severe break or injury in the soft tissue of the skin, which 
may include trauma from sharp or blunt object [17, 18]. Iatrogenic wounds are wounds caused 
by medical practices such as radiotherapy burns, surgical wound dehiscence, 
chemotherapy-induced skin necrosis and Foley catheter-induced hypospadias, this is more 
common to see in cancer patients [19]. Burn wounds are the type of wounds caused by burns, 
which include thermal, electrical and chemical burns [17]. In this study, burn wounds are the 
major focus, more literature review is provided for burn wounds in section 2.1.5. 
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2.1.2 Length of Time Since Formation of Wounds 
 
Based on length of time since formation, the wounds can be categorized into acute 
wounds and chronic wounds [20]. Acute wounds are usually referred as wounds that can heal in 
6 weeks or shorter period [17, 21]. Without effective bacteria clearance, an acute wound can 
progress into a chronic wound [5]. Chronic wounds are wounds that don’t heal within 6 weeks 
period [17]. In section 2.2, more detailed description of chronic wounds is provided. 
 
2.1.3 Injury Mode of Wounds 
 
Based on the mode of injury, they can be categorized into the following types: abrasion, 
ulceration, incision, lacerations and degloving injury [17]. An abrasion is the wound that only 
involves the outer layer of the skin, a ulceration refers to the discontinuity or break in a bodily 
membranes that impedes the organs of which that membrane is a part from continuing its normal 
functions [22], if the wound occurs on the skin, it causes defect in epithelial lining [17]. Incisions 
are wounds caused by sharp objects such as needle. Lacerations are wounds caused by blunt 
objects such as stone. Degloving injury refers to a type of avulsion in which an extensive section 
of skin is completely torn off the underlying tissue [23].  
 
2.1.4 Contamination and Risk of Postoperative Infection 
 
Based on the contamination and risk of postoperative infection, the wounds can be 
categorized into: clean wound, clean/contaminated wound, contaminated wound and dirty wound 
[17]. Clean wound refers to the wound with no infection, only microflora can potentially 
contaminate the wound and no hollow viscus is contaminated with bacteria. Clean/contaminated 
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wounds indicate the wounds which hollow viscus such as respiratory, alimentary or 
genitourinary tracts with indigenous bacterial flora is opened under controlled circumstances. 
Contaminated wounds refer to open accident wounds encountered early after injury, with 
extensive introduction of bacteria into a normally sterile area of the body. Dirty wound refers to 
the traumatic wounds in which a significant delay in treatment has occurred and necrotic issue is 
present [17]. 
There are some other wounds categorization methods such as depth, site and complexity. 
Based on depth, the wounds can be categorized into superficial and deep wounds. Based on site, 
the wounds can be classified into midline laparotomy, suprapubic and thoracotomy and so on. 
Based on complexity, the wounds can be categorized into simple, complex and complicated 
wounds [17]. 
 
2.1.5 Burn Wounds Introduction 
 
Burn wound is the major focus of this study, it is one of the most common and 
devastating forms of trauma, even though the surface of a wound is sterile immediately after 
injury, the site will eventually be colonized with bacteria [24], and infections on burn wounds 
pose serious possibility of complications that can occur in the acute period following injury [25] 
as thermal destruction caused by burn has impact on the skin barrier system and accompanying 
local and systemic immune response, thus compromising the integrity of the skin and the 
immune system, which plays key roles in  contributing to infections for patients with severe 
burns [1-3]. There are various microorganisms that can accumulate on the burn wound sites, 
among them, gram-positive bacteria S. aureus and gram-negative bacteria P. aeruginosa are still 
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the major infection sources [4]. The wound site is a protein rich environment which provides an 
excellent environment for bacteria colonization and proliferation [24, 26, 27]. 
Same way as regular wounds, burn wounds are also subject to biofilm formation [28, 29], 
persister cells within the biofilms can temporarily disable the inherent mechanism of cell deaths 
on the biofilm which is resistant to the antibiotic treatments and thus lead to failure to eradicate 
the biofilms [6, 30, 31]. Animal studies on cutaneous burn wounds show that mature biofilms 
can be formed in 48 to 70 hours, and biofilms formed by P. aeruginosa on human burn wounds 
can be achieved in 10 hours [32]. Inhibition of biofilm formation or removing the existing 
biofilm developed on the wound site is the key issue in order to facilitate the wound healing 
process. 
 
2.2 Wound Healing Process 
 
In a typical wound healing process, there are five different phases: Injury, coagulation, 
inflammation, tissue formation and tissue remodeling [33-35]. Some papers would define the 
phases as hemostasis, inflammation, migration, proliferation and maturation [5, 36-39]. Each of 
these phases lasts a specific length of time, they are both interdependent and overlapping, 
together with various cellular and matrix components involved to act on the wound healing 
process in order to restore the damaged tissues [40, 41]. 
Injury can be caused by various reasons, examples include trauma, surgery, burn, 
infections, the injured cells will release cytokines such as PDGF [42-44], TGF-β [35, 45-48] and 
TGF-α [49, 50] to initiate subsequent wound healing phases. Immediately after the injury, the 
second phase of wound healing: coagulation or hemostasis would occur, with platelets 
accumulating at the wound site and fibrin clot forming [33, 38]. This process is accompanied 
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with the release of PDGF, TGF-β, EGF and TGF-α, as well as adhesive glycoproteins such as 
fibronectin [33] which help attract the fibrin clots to the wound sites. Inflammation is the third 
phase that usually occurs 1-5 days after injury, with neutrophils predominating in the first few 
hours of inflammation, and the phagocytosis of neutrophils sterilize bacteria and foreign bodies 
present at the wound site [33]. Later in the process, macrophages, which are the most important 
inflammatory cells [51], will outnumber the neutrophils. Still through phagocytosis, 
macrophages decontaminate the wound sites, along with various growth factors such as PDGF, 
TGF-β, FGF [52, 53], the existence of macrophages signals the transition from inflammatory 
phase to tissue repair phase. In this phase, there will be re-epithelialization and granulation 
involved. Re-epithelialization is served as reestablishment of epidermal barriers to protect the 
internal organs, while granulation is formed by macrophages. Fibroblasts and endothelial cells 
move into the wound site, with fibroblasts constructing new extracellular matrix to support cell 
growth [33]. Following this is the phase of tissue remodeling, with attempt to return the damaged 
tissue to its original condition prior to injury. 
If acute wounds are not treated properly and are colonized by bacteria, they may progress 
into chronic wounds. Chronic wounds are wounds that do not heal in an orderly set of stages and 
in predictable amount of the time as most wounds do. Wounds that do not heal within three 
months are often considered as chronic wounds [54]. Most chronic wounds can be classified into 
three major types: pressure ulcers, venous ulcers, and diabetic ulcers, and the causative factors 
can be categorized into four types: local tissue hypoxia, bacterial colonization, repetitive 
ischemia reperfusion injury, and for elderly patients, an altered cellular and systemic stress 
response can also be the cause for chronic wound [55]. All chronic wounds have measurable 
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bacteria counts [56], and critical colonization is by itself sufficient to result in a chronic wound 
[57], thus clearance of bacteria on the wound sites is critical. 
 
2.3 Bacteria and Impact on Wound Healing 
 
2.3.1 Bacteria Infection 
 
The healing process as stated in Section 2.2 is expected to occur in a chronological order 
without disruption or delay, any discrepancies or prolongation of this process may result in 
delayed wound healing. There are a number of factors that impact the wound healing process, 
which can be basically categorized into local and systemic [5]. The local factors examples 
include oxygenation, infection, foreign body, venous sufficiency, while the systemic factors 
include age and gender, sex hormones, stress, ischemia, diseases like diabetes, obesity, 
medications, alcoholism and smoking. 
Bacteria however, play an important part in delaying wound healing, and evidence 
showed that bacteria infected patients have higher rate of mortality [58]. Once the skin is injured, 
microorganisms will obtain access to the tissues beneath the skin. There are different states of 
infection based on the severity of replication, these include: contamination, colonization, local 
infection, critical infection and spreading invasive infection [5], each condition is more serious 
than the last. Contamination is merely the presence of non-replicating microorganisms. 
Colonization refers to the presence of replicating microorganisms on the wound site without 
damage of the tissue. Local infection and critical infection mean the replication of organisms and 
the following tissue responses. Invasive infection is the presence of replicating organisms with 
actual host injury [59]. During the normal inflammatory process, the removal of invading 
microorganisms is crucial, the incomplete microbial clearance will result in prolonged 
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inflammatory phase, if this continues, the wound may enter a chronic state with inability to heal 
by itself. Prolonged inflammation can also lead to extracellular matrix degradation and growth 
factor degradation [5, 59]. 
There are two major categories of bacteria that cause infection, Gram-positive and 
Gram-negative bacteria. The two categories show structural differences in their cell walls. 
Gram-positive bacteria have a thick layer of peptidoglycan while gram-negative bacteria do not. 
However, gram-negative bacteria are more resistant against antibodies because of their 
impenetrable cell walls [60]. 
 
2.3.2 Biofilms 
 
Another important element that inhibits wound healing is the biofilm formed by bacteria 
colonies. Biofilms are of complex composition made up by accumulated bacteria in a 
self-secreted EPS [59]. A mature biofilm will develop a protective mechanism which is more 
resistant to regular antibiotic treatments, it is a result of natural tendency of microorganisms to 
attach to wet surfaces, and to multiply and embed themselves in a slimy matrix [61]. Among all 
the microorganisms, S. aureus and P. aeruginosa are the most commonly found bacteria in 
infected wound sites according to the studies [4, 62]. 
Biofilms formation can be used to explain the ineffectiveness of antibiotics as treatment 
to chronic wounds due to its self-protection mechanism, however, the mechanism is not fully 
understood yet, but there are studies that proposed several models to explain the mechanism, 
including physical or chemical diffusion barriers to antimicrobial penetration, biofilm slow 
growth, activation of the biofilm general stress response and so on [63]. The protection 
mechanism can also differ depending on the bacterial complement of the biofilm and the agent 
11 
 
used to treat it. In the meantime, the environmental heterogeneity within the biofilm can promote 
the formation of a heterogeneous population of cells, thus different levels of resistance can be 
expressed throughout the biofilm community, which altogether contribute to the antibacterial 
mechanism to regular antibiotics [64, 65]. 
Ideally, biofilm should be prevented instead of being treated, however, the currently there 
is no known existing technology that can successfully prevent or control the formation of 
unwanted biofilms without causing side effects [61]. The main strategy used to prevent the 
formation of biofilm is to clean and disinfect the wounded area before biofilm develops and 
firmly attaches to the surface [66, 67]. Biofilm detectors were already developed to monitor the 
surface colonization by bacteria and allow control of biofilm formation in early stages [68, 69]. 
Antibiotics are relatively ineffective for eradicating biofilm infections, and very high 
doses are required to reduce biofilm presence [70]. Mupirocin irrigation, gentian violet, and 
thiamphenicol glycinate acetylcysteine can effectively eradicate biofilms [71-73]. Physical 
disruptions, surfactants and probiotics are also reported to be able to eradicate biofilms [74]. 
Metal compounds such as Ag and ZnO are also very effective against biofilm eradication [75, 
76]. However, there are no studies that researched on effectiveness of ZnS on eradicating S. 
aureus biofilms. 
 
2.3.3 Drug Resistant Bacteria 
 
The threat of infection is made worse by drug resistant bacteria. With high rates of 
nucleotide substitution and poor mutation error-correction ability, the bacteria have high capacity 
to adapt to new hosts including human [7, 77, 78]. One example of these types of bacteria is 
MRSA [79], which has become an increasingly serious issue. MRSA was first isolated in the 
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early 1960s [80], it is the strain of S. aureus that acquired the mecA gene which expresses the 
methicillin resistance [81], but it is also resistant to many antibiotics including penicillin [82]. 
MRSA infection resulted in mortality rates of 22% in 2000 [83], and mortality rates have been 
dramatically increasing from 1993 to 2002 period [84]. In another study, invasive MRSA 
resulted in death rates of 19% in 2007 in United States [85]. 
 
2.4 Antibacterial Mechanisms 
 
2.4.1 Cell Death Induced by Oxygen 
 
Although the human body has self-healing functions, acceleration of wound healing is 
still preferable. By controlling infection, effective topical antibacterial therapy can decrease the 
conversion of partial thickness to full thickness wounds [4]. Topical antibacterial agents are 
applied directly to the wound sites, major mechanisms of antibacterial actions include: inhibition 
of cell wall synthesis, inhibition of protein synthesis, inhibition of nucleic acid synthesis, 
inhibition of metabolic pathways and interference with cell membrane integrity [86-90]. 
In the natural process of wound healing, oxygen plays an important role [35, 91-93], 
besides providing oxygen needed for metabolism which generates energy during the wound 
healing process, some oxygen is used to convert into highly reactive ions as well as ROS, 
including superoxide ions and hydrogen peroxide, which are essential for infection prevention in 
the inflammatory phase. ROS like H2O2 and O
2-
 can be produced by neutrophils and 
macrophages during the wound healing process [35], which can cause DNA damage, lipid 
peroxidation, protein damage, and oxidation of important enzymes [94]. Also, generation of ROS 
can cause disruption of ATP production of the cells [95]. All these effects are able to kill the 
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colonized bacteria at the wound site. ROS generated by other substances like Ag nanoparticles 
and Zn ions are also proven to have antibacterial properties [95-98]. 
 
2.4.2 Cell Death Induced by Membrane Damage 
 
Membranes are important components for the cells, they separate the interior of cells 
from the outside environment [99], they maintain the structure of cells, and they are selectively 
permeable to ions and organic molecules, and control the movement of substances in and out of 
cells. Membranes are also important to transport nutrients and wastes, which involve active 
transportation. Signaling and marking are also important functions for membranes in order to 
identify cells from each other and process signals received from the extracellular environment 
[100]. Overall, membranes play crucial roles to support lives of cells, destruction of cell 
membranes can cause leakage of cellular proteins which will stop cell functioning and eventually 
kill the cells, and many studies showed that the antibacterial properties stemmed from particles 
deposition on the membranes which stopped cell functioning [101-103]. 
 
2.5 Topical Antibacterial Drugs for the Treatment of Burn Wounds 
 
2.5.1 Antibiotics 
 
There are many different types of antibacterial agents, selection of topical drugs should 
be based on the ability to inhibit microorganisms growth [4]. The typical and most commonly 
used are antibiotics.  
Antibiotics have been used for wound treatment for a very long time. Penicillin, for 
example, has been used as an antibacterial agent since 1929 [104]. Penicillin served as a very 
effective method to eliminate mortality of burn wound patients [105, 106]. Many other types of 
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antibiotics were also used such as methicillin [107], gentamicin [108, 109], erythromycin [110], 
and neomycin [110, 111]. However, development of antibiotic resistance has become an 
emerging problem [79, 112, 113], especially after widespread use of antibiotics in recent decades 
[8, 114]. One of the most representative examples is MRSA which was previously mentioned in 
Section 2.3.3, it is not only resistant to methicillin, but is multi-resistant to many different 
antibiotics [115]. Studies have already proven a clear association between the overuse of 
antibiotics and MRSA isolation [116]. Thus antibiotic treatment continuously relies on the 
development of new antibiotics, as for example, daptomycin [115]. The mechanisms of how 
antibiotics kill bacteria is still not clearly determined, however, the following two models were 
proposed to explain the possible antibacterial mechanisms: inhibition of DNA replication, 
protein translation and ATP generation, induction of ROS formation, inhibition of cell walls 
formation [104]. 
 
2.5.2 Ag Containing Agents 
 
One commonly studied family of topical antibacterial agents is Ag and Ag containing 
compounds, this family includes Ag simple substances, Ag proteins, Ag salts and Ag compounds 
[117]. Ag has long been used as an antimicrobial agent since the 1800s [118, 119], but the 
interest of using Ag as an antibacterial agent declined since the discovery of antibiotics. 
However, the trend of using Ag has regained popularity in the past two decades due to the 
emerging problem of antibiotics resistant bacteria [119]. Ag simple substances, especially Ag 
nanoparticles, possess a broad spectrum of antimicrobial properties, including being active 
against MRSA [120-123]. Since the commencement of nanotechnology, Ag nanoparticles have 
drawn special attention for its high surface area to volume ratio and unique chemical and 
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physical properties [124, 125]. Ag protein refers to small proteins attached with Ag or Ag 
nanoparticles suspended in protein binder, with the purpose of enhancing solubility in solution. 
Although they possessed antibacterial properties, they are much less effective than ionic Ag or 
metallic Ag compounds, thus were replaced by Ag salts in the 1960s [117]. There are many more 
types of Ag salts that are applied for wound healing, since the Ag ions are highly bactericidal 
[117]. Typical examples of Ag salts include: silver nitrate, silver sulfate, silver chloride [126]. 
The effective antibacterial properties are due to their high solubility. However, the solutions are 
usually unstable when exposed to light, as they produce black stains. Also, nitrate is toxic to 
wounds and cells and seem to decrease the healing which is believed to offset the benefits of the 
antibacterial effect of Ag ions. The reduction from nitrate to nitride may cause oxidant induced 
cell damage, which is likely responsible for impaired re-epithelialization [117]. 
A typical example of a Ag compound is silver sulfadiazine, which was introduced in the 
1970s [127]. Ag is combined with propyleneglycol, stearyl alcohol and isopropyl myrislate and 
mixed with the antibiotic sulfadiazine in order to produce a combined formulation [117]. Among 
many Ag burn wound agents with combinations of sulfur, silver sulfadiazine appeared to display 
the most effectiveness in vitro tests [128]. However, there are also reports claiming that the silver 
sulfadiazine has poor usefulness on burns [129]
 
and overuse of silver sulfadiazine may cause 
potential risk of silver toxicity [130]. 
Although the antibacterial mechanism on infection has not been clearly identified, there 
are reports that document how Ag plays a role in wound healing. Ag is biologically active when 
it is in soluble form, either as Ag
+
 or as Ag
0
 clusters, Ag
+
 is found in Ag proteins, salts and other 
ionic compounds like silver sulfadiazine. Ag
0
 on the other hand, is found in metallic Ag like Ag 
nanoparticles [119]. Free Ag ions can destroy microorganisms immediately by blocking cellular 
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respiration, stopping ATP production and disrupting the function of cell membranes, especially 
when they are bound to the tissue proteins, thus causing the structure of the cell membrane to 
change and eventually kill the bacteria. Also, Ag ions are able to bind and denature the cell DNA 
and RNA, which also hinder cell replication [95, 131-133]. Ag nanoparticles, due to their small 
dimensions of 100 nm or less, possess unique properties like catalytic capabilities and ability of 
generating ROS [134], smaller sized Ag nanoparticles with 10nm in diameter or less may pass 
through or directly deposit on the cell membrane and accumulate on the intracellular 
nanoparticles thus leading to cell malfunctioning [95, 126]. Overall, the major components that 
contribute to the antibacterial properties for wound healing are Ag ions and metallic Ag 
nanoparticles. Although Ag is proven to possess antibacterial properties against a wide spectrum 
of bacteria, there has been reports about the development of Ag resistant bacteria due to overuse 
of Ag as wound care, which poses danger to current burn wound management [9, 10]. And in 
actuality, bacteria are able to gradually develop resistance over many different toxic metal ions 
[135]. 
 
2.5.3 Zn Containing Agents 
 
Another family of metallic compounds used for wound healing are Zn ionic compounds 
with typical examples being zinc oxide [136], zinc sulfate [137], zinc chloride [138], zinc 
sulfadiazine [139] zinc sulfide [12]. ZnO is a common therapy for various skin disorders as it is 
protective, astringent and antibacterial [140], and it is effective on both Gram-positive and 
Gram-negative infections. ZnO, when produced in nanoscale, will exhibit excellent antibacterial 
properties, and the effectiveness is inversely proportional to the size of the ZnO particles, this 
finding is applicable for sizes changed by either synthesis methods or mechanical methods [15, 
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141, 142]. ZnSO4 has been proven to be able to assist wound healing by taking it orally as it 
provides necessary nutrients for protein synthesis [143, 144]. However, although it is not widely 
used as an antibacterial agent for burn wound healing, ZnSO4 has been listed by pharmacopoeias 
as a local astringent and antiseptic [145]. ZnCl2 is used as an escharotic after burn injury, as it is 
soluble in water, it results in higher Zn ions concentration on the wound sites [137]. Zinc 
sulfadiazine, as suggested by the name, contains the antibacterial compounds sulfadiazine, and 
exhibit antibacterial properties to common burn wound infection bacteria like P. aeruginosa 
[139, 146]. This compound is more economical than its Ag counterpart silver sulfadiazine [146]. 
ZnS, which this review will discuss in more in detail in the later paragraphs, has also been 
reported by very few studies in relation to its antibacterial properties [12-14]. However, its 
application has not been extensively studied. 
In terms of antibacterial mechanism, similar to Ag, there are also two major contributors 
for the antibacterial properties, the Zn ions and nanoparticles themselves. The production of 
increased levels of ROS caused by Zn ions [147, 148], such as hydroxyl radicals and singlet 
oxygen, and the deposition of nanoparticles on the surface of bacteria which cause disruption and 
disorganization of membranes are the main reasons that cause the bacteria cell death [141]. 
Similar to Ag, smaller sized nanoparticles show better antibacterial properties, it is particularly 
interesting that mechanically grinded ZnO shows better antibacterial properties due to the 
decrease of lattice distance as a result of mechanical grinding, which induces more formation of 
H2O2 on the particle surface [15, 149], and thus are more capable of killing bacteria. Although 
bacteria are capable to develop metal ion resistance, there have not been reports on Zn resistant 
bacteria for burn wound infection. Zn is relatively harmless by comparison to Ag, only exposure 
to high doses has toxic effects, making acute Zn intoxication a rare event [150]. 
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2.5.4 Other Antibacterial Agents 
 
Besides the antibacterial agents mentioned in the previous sections, there are also many 
other types of agents for burn wound infection control. Nystatin has been reported to possess 
antifungal properties [151], povidone iodine is also believed to help wound healing [152], 
however, its effectiveness is also questioned and even criticized for impairing wound healing and 
reducing wound strength [152, 153]. Pexiganan is a 22-amino acid peptide isolated from the skin 
of frogs and is drawing interests on wound healing aspect, it is also effective on S. aureus and P. 
aeruginosa. However, its antibacterial mechanism and application studies are still underway 
[154]. Other examples include nitrofurazone [155], nitrofurantoin [156], chlorhexidine [157], 
sodium hypochloride [110, 158]. 
 
2.5.5 Zinc Sulfide 
 
As mentioned in the previous sections, very few studies have been conducted on ZnS 
antibacterial properties. In these studies, ZnS particles were chemically synthesized. In the 
following study, TAA was used as precursor for sulfur and Zn(Ac)2 as precursor for Zn [12], 
during the reaction, the surfactant Fc-loaded DDAB were dissolved to acquire more uniform 
distributed particle sizes. The solution was then heated at 80 °C in a water bath and maintained 
for 6 hours with magnetic stirring, and the white precipitates were acquired using centrifugation 
and dried in vacuum. The ZnS particles as synthesized were tested on E. Coli, a typical 
gram-negative bacteria on agar plate assay. The result of this study has shown that the viable 
colonies on the plates were reduced significantly as the concentration of ZnS particles increased, 
the experiment also showed that by comparison to more commonly used antibacterial agent ZnO, 
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ZnS has more efficient antibacterial properties. The ZnS nanoparticles have also been proven to 
be able to deposit on the surface of bacteria and inhibit the regular bacteria functions thus killing 
the bacteria [13]. However, other studies demonstrated that ZnS possesses better antibacterial 
properties after oxidation which resulted in formation of ZnO [159]. Another study on the 
chemical precipitation method uses ZnCl2 and Na2S as precursors for the reactions to create ZnS 
nanoparticles [14], the particles had an average diameter of 2-4 nm. In order to assess the 
antibacterial properties, disk bacteriological tests on P. aeruginosa, Actinomycete and 
Salmonella typhi were conducted. The result concluded that ZnS showed different antibacterial 
effectiveness against different bacteria, it also has different effectiveness when applied with 
different concentrations. The general trend is the higher the concentration, the larger the ZOI 
area. Based on this study, the ZnS is most effective on Salmonella typhi. In another relevant 
study, ZnS also showed antibacterial activity over B. subtilis and K. planticola [16]. 
Overall, many different types of topical antibacterial agents have been reported, 
antibiotics and typical metallic compounds like Ag and ZnO have been reported extensively. 
However, very few studies have been done on antibacterial effectiveness of ZnS particles. Based 
on the information provided in the previous sections, the bacteria used for the study of ZnS 
antibacterial effectiveness did not include the most commonly seen burn wound infection 
bacteria strain S. aureus. Further investigation is needed to validate the antibacterial 
effectiveness of ZnS on this particular type of bacteria strain. 
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2.6 Synthesis of ZnS 
 
2.6.1 Chemical Synthesis of ZnS 
 
There are two major ways to synthesize ZnS [12, 16], one is chemical precipitation 
method, and the other is biological synthesis. The chemical synthesis requires precursors of Zn 
and sulfur, and the reaction takes place in a solution based environment, usually requiring 
heating under different temperatures. In order to control the size of the precipitates, different 
parameters are involved, and many of them usually require stabilizing agents that control the 
shape of the precipitates. Typical precursors for Zn include: zinc chloride [14, 160], zinc acetate 
dihydrate [12, 161-164], zinc nitrate hexahydrate [165, 166], zinc sulfate [167]. And typical 
precursors for sulfur include: 1-thioglycerol [161], TAA [162, 165, 166], thiourea [163, 164], 
sodium sulfide [14]. The basic reaction mechanism is shown below in Equation (2.1): 
Zn
2+
 + S
2-
  ZnS                           (2.1) 
G. R. Amiri and his group used ZnCl2 as Zn precursor and Na2S as sulfur precursor, and 
ME or starch was used as surfactants. The reaction took place in distilled water. ZnCl2 was added 
first followed by adding of ME or starch, Na2S was added at last under vigorous stirring. The 
experiment was done under room temperature. After the reaction, the ZnS precipitates were 
centrifuged and dried [14]. 
Gaiping Li and his group used precursor of Zn(Ac)2 and TAA for ZnS production. 
DDAB was used as surfactant. In the study, DDAB solution was prepared by dissolving DDAB 
into water, and Zn(Ac)2 and TAA were dissolved in the DDAB solution under stirring until all 
chemicals were completely dissolved. The crude solution was then heated to 80 °C for 6 hours. 
After the reaction, the ZnS precipitates were centrifuged and dried [12]. 
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J. Nanda and his group used Zn(Ac)2 as Zn precursor and Na2S as sulfur precursor, 
however, 1-thioglycerol was used as capping agent to control the particle size [161]. Zn(Ac)2 and 
Na2S were dissolved in DMF, then the solution was stirred under argon atmosphere. 
1-thioglycerol was added in the solution, the solution was stirred for 8-10 hours, and then the 
ZnS precipitates were centrifuged and dried. 
Jin Joo and his group studied the generalized and facile synthesis of metal sulfide 
nanocrystals in which the synthesis of ZnS was also studied [160]. This study also used ZnCl2 as 
precursor for Zn, but used sulfur simple substance as precursor for sulfur. The reaction took 
place in oleylamine solution with presence of TOPO as surfactant. Zinc-oleylamine-TOPO 
solution was prepared by heating up to 170 °C for 1 hour, sulfur was later added. After that, the 
solution was heated to 320 °C and aged for 1 hour. After the reaction, the ZnS particles were 
centrifuged and dried. 
Subhendu K. Panda and his group studied the optical properties of ZnS nanospheres 
[166]. In this study, they used the one-pot colloidal synthesis. Precursor used for Zn was 
Zn(NO3)2 and the precursor for sulfur was TAA. PVP was used as stabilizer for spherical 
structures. First PVP was dissolved in water followed by Zn(NO3)2 under vigorous stirring. After 
that, TAA was added and the solution was heated at 80 °C for 2 hours. Later the ZnS precipitates 
were centrifuged and dried. 
In order to create different shapes of ZnS particles, the use of different agents or methods 
is involved. For photonic applications, spheres with ZnS as shell and silica as core were 
developed. The reaction took place with silica spheres in the solution under sonication, and the 
ZnS grew onto the silica particles [165]. In order to create spherical ZnS particles, PVP was used 
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as stabilizer to aggregate the ZnS particles to create a spherical structure [166]. By changing the 
reaction environment, we can also get hollow ZnS spheres [164]. 
With regards to controlling the size of ZnS particles, changing the precursor composition 
will have an impact [161]. Some other parameters during the reaction are also reported to have 
impact on the final particle sizes of ZnS, such as reaction time and temperature [164, 166]. 
Generally, the longer the reaction time, the larger the particle size, and the higher the 
temperature, the larger the particle size [164, 166]. 
 
2.6.2 Biological Synthesis of ZnS 
 
The traditional chemical production methods have some problems, including poor 
reproducibility, some require high temperature, or high pressure to initiate the reaction, some 
methods may use or produce toxic matters such as H2S in the process [11]. So recently, the 
biosynthesis methods, which are generally considered as more eco-friendly, cleaner, more 
economical and more reproducible [16], have attracted much attention. Biological synthesis 
usually requires SRB or metal reducing bacteria in an anaerobic environment, the end products 
of SRB metabolism under an anaerobic environment, sulfide, can react with metal ions and 
create insoluble metal sulfide [168]. Different pH values in the environment will result in 
different forms of sulfide (S
2-
, HS
-
 or H2S) [169], thus controlling pH plays an important role in 
ZnS production in the biosynthesis. Besides the requirement of the medium and environment as 
described in the previous section, incubation time, temperature, supplement nutrients and their 
amounts, bacterial species and precursor types can all have impact on the particle size of ZnS 
[16]. 
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Studies showed that the biosynthesized ZnS nanoparticles are usually bound to proteins, 
these proteins can not only facilitate keeping the nano dimension of ZnS particles, but also 
increase aggregation, which can prevent redissolving of ZnS nanoparticles into the solution and 
incidental uptake by sulfate reducing bacteria which may in turn kill the cells [16, 170]. There 
are two major pathways for the proteins to bind on ZnS: first, proteins, peptides or amino acids 
could be released after sulfate reducing bacteria cell death and then captured by hydrophobic 
ZnS surfaces, and alternatively, bacteria can generate toxic metal-binding proteins themselves 
and bind to ZnS [170]. This is likely due to the bacterial resistance mechanism to heavy metals 
and metalloids [171]. 
Another important characteristic that biosynthesis possesses is the scale-up potential and 
the reduced cost based on larger scale production. The exponential growth of bacteria is 
currently of great economic importance in terms of the production of a wide variety of microbial 
products [172]. For laboratory scale cultivation, certain costly media components might be 
needed, but for industrial purposes, they should be economical and readily available [173]. 
Among various fermentation methods, the in vitro Liquid State Fermentation (LSF) will have 
large positive effect of economy of scale-up production [174]. Using this method, the 
biosynthesis study of ZnS particles have demonstrated that even with scalability factor of 2400 
of medium scale, the production remains stable and the quality of the ZnS nanoparticles showed 
no significant difference in comparison to small scale production [16]. Thus biosynthesis of ZnS 
particles can be more economical to scale up and produce in bulk. 
In the meantime, studies showed that in the laboratory environment, the productivity of 
ZnS particles is still relatively low comparing to chemical production, the daily average ZnS 
production rate of 1 L medium is about 0.5 g, while study showed that chemical production can 
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produce around 30 g every 3 hours using 1 L solution [16, 166]. However, as the biosynthesis of 
ZnS has not yet been commercialized, the costs for bulk synthesis cannot be evaluated at this 
time. 
 
2.7 Cryomilling 
 
Cryomilling is the mechanical attrition of powders under a cryogenic environment. It is 
often used as a method of strengthening materials through grain size refinement and dispersion 
of fine, nanoscale particles, mostly for metallic application. It involves the transformation of 
plasticity-induced dislocation structures into high angle grain boundaries in metallic powders 
under liquid nitrogen environment [175]. Other than grain size refinement, it is usually used to 
decrease particle sizes [176]. Cryomilling combines both the environment of cryogenic 
temperatures and conventional mechanical milling. The extremely low temperature suppresses 
recovery and recrystallization of the materials, which in turn leads to finer grain structures and 
more rapid grain refinement [177], so that the desired nanostructures can be reached in shorter 
time in comparison to conventional mechanical ball milling [178]. A study showed that direct 
ball milling of Zn under regular environment results in ZnO particles [179], which indicates that 
rapid oxidation takes place during regular ball billing process. However, as cryomilling operates 
under a cryogenic environment, a high rate of oxidation is avoided which can only be achieved 
when materials are sealed in inert gas environment for regular ball milling [178, 180]. 
As particle size has been decreased through cryomilling, the surface to volume ratio is 
increased accordingly. Researchers have found that in nanoparticles, small dimension results in 
large surface to volume ratio, yielding to increase of the chemical activity [181]. Although few 
papers have reported the effect of cryomilling on antibacterial properties, studies have been 
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conducted on the effect of ball milling on antibacterial properties. Generally, the longer the 
milling period, the smaller the particle size and the better antibacterial effectiveness the particles 
possess [15, 182]. The relationship between milling time and antibacterial activity as mentioned 
in the previous sentence applies to typical metallic antibacterial agents such as ZnO and Ag 
nanoparticles [183] and are thus expected to have the same effect on other antibacterial 
nanoparticles, and this is what this study is interested. 
 
2.8 Summary of Literature 
 
This literature review summarizes the key areas related to this study, which describe the 
following aspects: 1) Different types of wounds and their classifications, 2) burn wound healing 
process and common infections indicating the necessity of antibacterial agents during burn 
wound healing, 3) emerging problems of drug resistance and biofilm development which implies 
the importance of new drug development and 4) the necessity of using biosynthesis methods for 
fabrication of antibacterial substances. This literature review serves as fundamental knowledge 
basis for the development of this research. 
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CHAPTER 3. 
CHEMICALLY SYNTHESIZED ZNS ANTIBACTERIAL ACTIVITY EVALUATION 
 
 This Chapter is dedicated to demonstrate the pilot evaluations of the traditional methods of 
ZnS synthesis and its antibacterial effectiveness, which provided the rationale for the research 
developed for this thesis. This chapter contains four different sections: 1) Synthesis Method 
Selection; 2) Materials and Methods; 3) Evaluation Results; 4) Discussions. 
 
3.1 Synthesis Method Selection 
 
Chemical synthesis is by far the most popular method for ZnS production, Section 2.6.1 
has numerated different synthesis methods, and there are also many other chemical synthesis 
methods [167]. However, in terms of feasibility, the one-pot colloidal synthesis was the most 
favorable. Zn(NO3)2 and TAA were more economically available by comparison to other 
precursors. In the meantime, this synthesis method requires relatively low reaction temperature 
and shorter reaction time without special requirement for atmosphere. The reaction can be easily 
achieved in a regular laboratory environment. 
 
3.2 Materials and Methods 
 
3.2.1 ZnS Preparation 
 
PVP was purchased from Sigma Aldrich with average molecular weight of 40,000, TAA 
was purchased through Sigma Aldrich with > 99.0% purity, Zn(NO3)2·6H2O was purchased from 
Fisher Scientific. All chemicals were used without further purification. 
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In the preparation process, 3 g of PVP was dissolved in 90 ml of distilled water, then 0.03 
Mole, or 8.92 g of Zn(NO3)2·6H2O was added to the solution. After 1 hour of stirring, 0.03 Mole, 
or 1.50 g of TAA was added in the solution. Then the solution was stirred under 80 °C for 2 
hours. This process was conducted in fume hood, as H2S generated through the chemical reaction 
is hazardous. The solution was then cooled down to room temperature, the ZnS precipitates were 
then centrifuged, washed using distilled water and ethanol, and later dried in the vacuum oven 
overnight before ZnS particles were collected. 
The prepared ZnS nanoparticles were then cryomilled using freezer mill 6870 (SPEX, 
Metuchen, NJ, USA), which was operated under cryogenic environment of -196°C. 5 g of 
synthesized ZnS nanoparticles were used for cryomilling, and the parameters used were: 5 min 
precool, 8 cycles, 7 min run time for each cycle, 2 min cool time in between each two cycles and 
15 CPS for grinding. The total time period for grinding is 56 min [15]. The original 
as-synthesized ZnS sample was labeled as Comp C and cryomilled sample was labeled as Comp 
D. 
 
3.2.2 SEM Analysis 
 
The morphology of ZnS particles were imaged using JEOL JCM-6000 NeoScope 
Benchtop SEM. In order to clearly observe the morphology of the samples, the image was taken 
under 15 kV accelerating voltage, high vacuum, and magnification of 10000× and 5000×, using 
secondary imaging mode. The image was analyzed using JCM-6000 software version 1.1. 
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3.2.3 XRD Analysis 
 
The ZnS particles were analyzed using Rigaku MiniFlex 600 X-ray Diffractometer 
(Rigaku Inc, Woodlands, TX, USA) to determine the particles composition and the 
corresponding crystal structures. The voltage and current X-ray generator applied were 40 kV 
and 15 mA, with Cu as the source of X-ray, the detector used was NaI scintillator. The XRD 
profiles were analyzed using the Rigaku powder X-ray diffraction software PDXL version 
2.1.3.4. 
 
3.2.4 Bacterial Strains and Media 
 
As previously mentioned in Chapter 1, no study has been conducted on antibacterial 
properties of ZnS on common burn wound infection S. aureus. In this evaluation, evaluation was 
done on S. aureus and all the organisms will be stored at -80 °C until use. Bacteria were grown 
in either LB Broth or on LB Agar plates at 37 °C. The strain used was S. aureus AH133 which 
carries plasmid pCM11 which contains the gene that codes for the GFP [184]. 
 
3.2.5 ZOI Assay 
 
The bacteria were grown in LB broth, until the media were visibly turbid, and then the 
suspension was diluted until turbidity at OD600 of 0.5 was reached. The turbidity was measured 
using spectrophotometer. At this OD600 level, there are approximately 10
8
 CFU per ml. Normal 
PBS (pH = 7.4) was used to adjust the desired optical density. The LB agar plates were 
inoculated within 15 min after the inoculums suspension has been adjusted. A sterile cotton swab 
was dipped into the bacterial suspension, and a confluent lawn of bacteria was made on each 
plate using the dipped cotton swab. Within 15 min after the plates were inoculated, 50 mg of ZnS 
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powders were distributed at three spots onto the LB Agar surface, with at least 24 mm (center to 
center) between them [185]. The plates were incubated at 37 °C for 24 hours before results were 
read. The diameters of the zones of complete inhibition, including the diameter of the disk, were 
measured to the nearest second decimal place. 
 
3.3 Evaluation Results 
 
3.3.1 Morphology 
 
 Figures 3.1 and 3.2 showed the morphologies of Comp C and Comp D. The Comp C 
showed very uniform size distribution, with mean diameter of each individual nanosphere of 356 
nm with 21 nm of standard deviation. However, although it is expected that cryomilling 
decreases the particle size, due to agglomeration effect, Comp D actually showed an increase of 
mean diameter which is 1.068 µm and standard deviation of 1.052 µm. Also, due to cryomilling, 
the morphology of ZnS particles has turned from sphere to arbitrary shapes with sharp edges. 
This is possibly due to aggregation effect that holds small individual particles into a larger bulk 
[16]. 
Cryomilling in this case has introduced agglomeration to the particles, as the technology 
can mill the particles into submicron in size, and they have the tendency to agglomerate and form 
the conglomeration with size as big as 50 µm or larger due to the presence of electrostatic, steric 
and van der Waals forces between particles [186-188]. Agglomeration is different from 
aggregation. Agglomerates are an assembly of primary particles, and the total surface area does 
not differ appreciably from the sum of specific surface areas of primary particles [189]. Thus 
even though the particle size of Comp D seemed larger than the non-cryomilled samples Comp C,  
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the agglomeration effect does not impact the amount of surface area in contact with PEG, and 
surface area to volume ratio was still expected to increase comparing to non-cryomilled Comp C. 
 
Figure 3.1: SEM image of Comp C 
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Figure 3.2: SEM image of Comp D 
 
3.3.2 XRD Analysis 
 
 Figure 3.3 showed the XRD profile of the particles synthesized. The three major diffraction 
peaks corresponded to the (111), (220), (311) planes of crystalline ZnS, which matched with 
XRD profile of ZnS sphalerite. The result showed that ZnS sphalerite has a cubic crystal 
structure with 5.408620 Å in unit cell dimension. 
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Figure 3.3: XRD profile of the as-synthesized Comp C 
 
3.3.3 ZOI Assay 
 
Figure 3.4 showed the ZOI assay results for Comp C and Figure 3.5 showed the ZOI 
assay results for Comp D. Based on the ZOI assays, Comp C showed no antibacterial properties 
as there were no clear inhibition zones with 50 mg ZnS Comp A treatment at 3 different 
locations, while Comp D showed ZOI of average of diameter of 20.22 mm with standard 
deviation of 0.83 mm. 
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Figure 3.4: ZOI assay result for Comp C 
 
Figure 3.5: ZOI assay result for Comp D 
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3.4 Discussion 
 
This evaluation has provided basic information of chemical synthesis of ZnS and its 
antibacterial properties. Based on the morphological SEM results, one-pot colloidal synthesis 
successfully produced monodispersed ZnS nanoparticles with mean diameter of 356 nm with 21 
nm of standard deviation, but cryomilling has dramatically changed the morphologies of the 
particles, making the particle size larger and with larger standard deviation. However, this may 
be due to the aggregation effect [188]. According to the XRD profile, the synthesized particles 
were ZnS sphalerite. 
 The ZOI results showed different results for Comp C and Comp D. Comp C basically 
showed no antibacterial properties against S. aureus. Although there are studies that showed 
as-synthesized ZnS has antibacterial properties against certain bacteria [12, 14], this study 
showed that the as-synthetized ZnS did not have a broad spectrum of antibacterial properties, and 
specifically might not have antibacterial properties against S. aureus. However, in this 
evaluation, Comp D showed very clear inhibition zones, which indicated that cryomilling has 
positive effect on antibacterial properties. 
Study showed that under certain PVP/Zn
2+
 ratio, PVP could encapsulate the ZnS 
nanoparticles, so that the ZnS would be passivated [190], thus the Zn
2+
 might be unable to be 
released to act upon the bacteria to inhibit the bacteria growth. In the meantime, PVP is basically 
non-toxic [191] and will not impact bacteria growth, this might explain why Comp C, which 
could be passivated by PVP, did not show antibacterial properties. However, based on the SEM 
analysis, cryomilling deformed the particles morphologies and could destroy the encapsulation 
on the outside layer, so that the Zn
2+
 would be easier to be released to act on bacteria. The 
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reasons above could possibly explain the fact that Comp D showed good antibacterial properties 
while Comp C did not. 
Therefore, based on the following reasons, the major part of this study will focus on  
understanding and further improving via cryomilling the antibacterial properties of biological 
synthesis of ZnS: 1) chemically synthesized ZnS did not show antibacterial effectiveness against 
common burn wound S. aureus infections; 2) the chemical production usually requires special 
conditions including high temperature, inert gas environment as described in section 1 of this 
chapter; 3) the chemical process usually involves H2S production which is hazardous for human 
beings and the environment; 4) biological synthesis is usually more biocompatible, and biosafe 
as mentioned in the literature review. 
As cryomilling proved to have positive effect on antibacterial properties over the 
as-synthesized ZnS, this study will continue to use cryomilling as a material refining process in 
expectation to enhance the antibacterial effectiveness. 
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CHAPTER 4. 
EFFECT OF CRYOMILLING ON ZINC SULFIDE EFFECTIVENESS AS 
ANTIBACTERIAL SUBSTANCE FOR BURN WOUND HEALING 
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4.1 Abstract 
 
This study introduced a novel antibacterial agent, zinc sulfide nanoparticles, for burn 
wound treatment against common infectious bacteria Staphylococcus aureus. Zinc sulfide 
nanoparticles were synthesized using Sulfate Reducing Bacteria under anaerobic environment, 
and the synthesized nanoparticles were further processed through cryomilling. Scanning electron  
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microscopy and X-ray diffraction techniques were used to characterize the morphology and 
crystal structure of the zinc sulfide nanoparticles. To assess bacteria inhibition and elimination, 
in vitro zone of inhibition studies consisting of inoculating cellulose disks on agar plates with 
Staphylococcus aureus followed by incubation for 24 hours were performed. In vitro biofilm 
models consisting of inoculating cellulose disks on well-developed Staphylococcus aureus 
biofilm on agar plates followed by 24-hour incubation were also conducted. Confocal laser 
scanning microscopy was employed to qualitatively observe the antibacterial effectiveness of 
zinc sulfide as antibacterial agent and statistical analysis was performed to quantitatively study 
the effectiveness by counting the residual colony forming units on the cellular disks. Results 
showed that the zinc sulfide nanoparticles show antibacterial properties, and cryomilling showed 
a positive effect on the antibacterial properties of zinc sulfide 
Key words: Zinc sulfide, Antibacterial, Staphylococcus aureus, Cryomilling 
 
4.2 Introduction 
 
Burn wounds are one of the most common and devastating forms of trauma, and series of 
complications can occur as thermal destruction on the skin barrier system and accompanying 
local and systemic immune system can be critical contributor for the infections for burn patients 
[1-3]. Evidence showed that bacteria infected patients usually have a higher rate of mortality [4]. 
Removal of invading infections is crucial and the incomplete microbial clearance will result in 
prolonged inflammatory phase which can lead to transition from acute into chronic wound [5, 6], 
thus hindering the healing process. Various types of microorganisms are able to colonize the 
wound sites, and gram-positive bacteria usually dominate the microorganisms population 
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immediately after the burn [7, 8]. Among them a typical example is the gram-positive bacteria 
Staphylococcus aureus [9]. 
The development of biofilm can be a serious problem on the wound sites [10]. Biofilms 
are complex compositions made up by accumulated bacteria in a self-secreted extracellular 
polysaccharide matrix (EPS) [6]. A mature biofilm is able to develop a self-protective 
mechanism which is more resistant to regular antibiotic treatments than regular bacteria [11]. 
Burn wounds are also subjected to biofilm formation [12], persister cells within biofilms can 
temporarily disable the inherent mechanism of cell death, which in turn is resistant to antibiotic 
treatment and lead to failure of eradication of biofilm [13, 14]. Staphylococcus aureus is among 
those commonly isolated bacteria that can develop biofilms [12]. 
With the overuse of antibiotics and antibacterial agents, drug resistance has become an 
emerging problem threatening the world [15], and the resistance can be against both antibiotics 
[16, 17] and metallic compounds such as silver [18]. Bacteria have high rates of nucleotide 
substitution and poor ability of mutation error-correction, in general the genetically mutated 
bacteria have high capability to adapt to new hosts including human [19-21]. The biofilm 
developed by these bacteria pose even higher risk for human beings, thus the identification of 
alternative antibacterial substances is always necessary. 
Previous studies indicated that Zinc Sulfide (ZnS) possesses antibacterial properties 
against several types of bacteria, including E. Coli [22], P. aeruginosa, Actinomycete, S. typhi 
[23], B. subtilis and K. planticola [24]. However, no test has been carried out on Staphylococcus 
aureus. ZnS in this study was biosynthesized, which was more eco-friendly, reproducible and 
economical than chemical synthesis. Cryomilling is the mechanical attrition of powders under 
cryogenic condition [25], and it was applied as a post-synthesis fabrication process to decrease 
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particle size of as-synthesized ZnS. Smaller sized ZnS particles are expected to possess better 
antibacterial properties than larger sized particles [26]. 
 
4.3 Materials and Methods 
 
4.3.1 ZnS Preparation 
 
ZnS nanoparticles were extracellular synthesized using the fast-growing metal reducing 
thermophilic bacterial, Thermoanaerobacter, X513 [27]. Media used were modified from 
TOR-39 medium, which contained the following ingredients: NaHCO3, CaCl2·2H2O, NH4·Cl, 
MgCl2·6H2O, NaCl, hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) buffer, yeast 
extract and resazurin, with Oak Ridge National Laboratory (ORNL) trace minerals which include 
selenium, molybdate, vitamin mixture solutions and Phosphate Buffer Saline (PBS) [28]. No 
exogenous electron carrier substance or reducing agent was added to the anaerobic medium. The 
dissolved basal medium was boiled with N2 gas purging and cooled with continuous N2 purging. 
Incubation was initiated with inoculation of glucose, sulfur source such as thiosulfate or sulfite. 
After cell growth and development of S
2-
, aliquots of zinc chloride were (ZnCl2, reagent grade > 
98%) dosed. The precipitate of ZnS nanoparticles was recovered by centrifugation and washed 
four times with deionized water and stored as wet condensed samples or freeze-dried solid 
samples. The original ZnS particles were labeled as Comp A. 
The prepared ZnS nanoparticles were then cryomilled using a freezer mill 6870 (SPEX, 
Metuchen, NJ, USA), which was operated under a cryogenic environment of -196°C. 5 g of 
synthesized ZnS nanoparticles were used for cryomilling, and the parameters used were: 5 min 
precool, 8 cycles, 7 min run time for each cycle, 2 min cool time in between two cycles and 15 
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counts per second (CPS) for grinding. The total time period for grinding was 56 min [26]. 
Sample acquired using this method was labeled as Comp B. 
 
4.3.2 Scanning Electron Microscopy (SEM) Analysis  
 
The morphology of ZnS particles were imaged using JEOL JCM-6000 NeoScope 
Benchtop SEM. In order to clearly observe the morphology of the samples, images were taken 
under 15 kV accelerating voltage, high vacuum, and magnification of 5000×, using secondary 
imaging mode. The image was analyzed using JCM-6000 software version 1.1. 
 
4.3.3 X-ray Diffraction (XRD) Analysis 
 
The ZnS particles were analyzed using Rigaku MiniFlex 600 X-ray Diffractometer 
(Rigaku Inc, Woodlands, TX, USA) to determine the particles composition and the 
corresponding crystal structures. The voltage and current X-ray generator applied were 40 kV 
and 15 mA, with Cu as the source of X-ray, the detector used was NaI scintillator. The XRD 
profiles were analyzed using the Rigaku powder X-ray diffraction analysis software PDXL 
version 2.1.3.4. 
 
4.3.4 Bacterial Strains and Media 
 
All the organisms were stored before use at -80 °C to ensure low cell activity [29]. 
Bacteria were grown in Luria Bertani (LB) Broth at 37 °C. The strains used were Staphylococcus 
aureus AH133. This type of strain carries plasmid pCM11 which contains the gene that codes for 
the green fluorescent protein [30]. To maintain the plasmid, erythromycin was incorporated in 
the growth medium at a concentration of 1 µg/ml. 
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4.3.5 Zone of Inhibition (ZOI) Assays 
 
Bacteria were grown in LB broth, until the media were visibly turbid, and then the 
suspension was diluted until an OD600 of 0.5 was achieved. The turbidity was measured by 
spectrophotometer. At 0.5 OD600 level, there are approximately 10
8
 Colony Forming Unit (CFU) 
per ml [31]. PBS (pH = 7.4) was used to adjust the desired optical density. The LB agar plates 
were inoculated within 15 min after the inoculums suspension has been adjusted. A sterile cotton 
swab was dipped into the bacterial suspension, and a confluent lawn of bacteria was made on 
each plate using the dipped cotton swab. Within 15 min after the plates were inoculated, ZnS 
powders were distributed at three spots onto the LB Agar surface. Each spot contained 50 mg 
ZnS particles with at least 24 mm (center to center) between two spots [32]. The plates were 
incubated at 37 °C for 24 hours before results were read. The diameters of the zones of complete 
inhibition, including the diameter of the disk, were measured and rounded to the second decimal 
place. The diameter of the zone is related to the susceptibility of the isolate and to the diffusion 
rate of the drugs, but the larger the inhibition zone, the better the antibacterial properties. 
 
4.3.6 In vitro Biofilm Model CFU Analysis 
 
The biofilm assay was performed as previously described with some modifications [33]. 
Briefly, S. aureus Green Fluorescence Protein (GFP) bacteria were grown overnight, washed 
once with PBS (pH 7.4), re-suspended in PBS (pH 7.4) to an optical density (OD600) of 0.5 (10
8
 
CFU/ml), and serially diluted (10-fold).  Three sterile cellulose disks with diameter of 6 mm 
were placed on the surface of freshly prepared LB agar with at least 24 mm (center to center) 
between them, and 10 µl containing 10
2
-10
3
 CFU of tested strain was inoculated onto each disk. 
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The disks were then treated with ZnS particles mixed in 100 mg PEG (PEG Ointment Base, 
B1300, Spectrum, Gardena, CA, USA) in order to cover the whole disk. Due to the strong 
antibacterial properties exhibited by ZOI assay using 50 mg, the starting amount of ZnS used for 
biofilm study was also 50 mg. The quantity was gradually decreased until biofilm can no longer 
be completely eradicated. In this study, 25 mg, 15 mg and 10 mg were used. The plates were 
then incubated at 37 °C for 24 hours. Following incubation, the disks were rinsed lightly to 
remove any unattached bacteria, and the disks were examined by Confocal Laser Scanning 
Microscopy (CLSM) and CFU assay. In CFU assay, the disks were transferred to a 1.5 ml 
microfuge tube in 1 ml of PBS and sonicated for 10 minutes. The tubes were then vortexed for 1 
minute to disrupt and disperse the biofilm. Bacterial suspensions were serially diluted 10-fold in 
PBS, and 10 µl aliquots of each dilution and undiluted suspension were plated on LB agar. The 
plates were air dried and they were then incubated at 37
o
C for 24 hours before the results are 
read. The number of CFU/disk was determined as described above, using the formula CFU/disk 
= (CFU counted × dilution factor) × 100. All experiments were done in triplicate, and dilutions 
were also plated in triplicate. 
 
4.3.7 CLSM Analysis 
 
For in vitro studies, disks were treated with S. aureus GFP AH133 bacteria as described 
above for the in vitro biofilm model. After 24 hours of incubation, three control disks under PEG 
and three treated disks under ZnS in PEG were examined for the presence of S. aureus GFP 
AH133 biofilm by a CLSM. Visualization of the S. aureus AH133 biofilms was accomplished by 
using a Nikon A1+/AIR+ Confocal Microscope (Nikon Inc., Melville, NY, USA) with images 
acquired at 2 µm intervals through the biofilms. Two and/or three-dimensional images were 
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acquired using the Nis Elements Imaging software v. 4.20. Several image stacks of each biofilm 
were examined by CLSM, and the images were analyzed as previously described [34]. 
Experiments were done in triplicate. 
 
4.3.8 Statistical Analysis 
 
Results of the CFU assays were plotted with Prism® version 4.03 (GraphPad Software, 
San Diego, CA, USA) with 95% confidence intervals (CI) of the difference. Linear mixed effect 
model was used to model the experiment data in order to account for repeated measurements [35, 
36]. Shapiro-Wilk W test was used to determine the normality of the data due to its higher power 
based on small sample size comparing to other normality tests [37]. Levene’s test was used to 
test equal variance between treatment groups as it can be used to compare variances between two 
or more groups. One-way ANOVA was performed to check the difference in means between two 
or more treatment groups. One-tailed and Two-tailed Student’s t-tests were used to determine if 
the means between two groups are different [38]. Type I error rate is the possibility of incorrect 
rejection of a true null hypothesis, and a null hypothesis is the hypothesis that sample 
observations result purely from chance. Bonferroni correction was used to control the overall 
familywise Type I error rate during multiple comparisons as they will result in increase in Type I 
error rate [39]. The statistical analyses were performed using JMP® software (SAS, Cary, NC, 
USA). All tests were conducted with generally accepted designated Type I error rate of 0.05, 
implying that it is acceptable to have a 5% probability of incorrectly rejecting the null hypothesis 
[40, 41]. 
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4.4 Results and Analysis 
 
4.4.1 ZnS Morphologies: 
 
Figures 4.1 and 4.2 showed the morphologies of synthesized (Comp A) and cryomilled 
ZnS particles (Comp B). Due to aggregation effect of smaller sized particles, the original ZnS 
particles synthesized have an average diameter of 2.836 mm with standard deviation of 
1.499mm, while the cryomilled ZnS particles have an average diameter of 0.801 µm with 
standard deviation of 0.407 µm. Meanwhile, the shape of the particles has been altered from 
arbitrary shapes with sharp edges to more spherical shapes. Due to the decrease in size of the 
particles, the surface area to volume ratio has been increased. 
Based on the previous study of biosynthesis of ZnS, the average crystallite size (ACS) is 
around 6.5 to 10 nm. However, nanoparticles in aqueous solution have higher surface energy 
than bulk materials [42], and the resulting particles often become cemented together into 
aggregates. Because particles dispersed in liquid media are in constant thermal or Brownian 
motion, they exhibit a strong affinity for nanoparticles as they move through medium and collide 
[43], and the surface characteristics affect aggregation in dispersion [44]. In this case we saw 
very large original Comp A particles even though the ACS was produced in nanoscale. 
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Figure 4.6: SEM image of Original ZnS particles (Comp A) 
 
Figure 4.7: SEM image of Cryomilled ZnS particles (Comp B) 
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4.4.2 XRD Analysis 
 
Figure 4.3 shows the XRD profile of the particles synthesized for wound dressing and the 
reference profile for ZnS sphalerite structure. The three major diffraction peaks corresponded to 
the (111), (220), (311) planes of crystalline ZnS, which matched the XRD profile of ZnS 
sphalerite. The result showed that ZnS sphalerite has a cubic crystal structure with 5.394493 Å in 
unit cell dimension. 
 
Figure 4.8: XRD profile of the synthesized ZnS particles (Comp A) 
The results showed that Sulfate Reducing Bacteria successfully produced ZnS particles 
with a sphalerite crystal structure. Cryomilling as post synthesis process decreased the particle 
size as well as changed the shape of the ZnS particles. 
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4.4.3 ZOI Assay 
 
Figure 4.4 showed the ZOI assay result for 50 mg Comp A treatment on S. aureus AH133 
bacteria lawn, the treatment created the ZOI of average of 11.5 mm with standard deviation of 
0.656 mm in diameter. Meanwhile, Figure 4.5 showed the ZOI result for 50 mg Comp B ZnS 
treatment, the treatment created a ZOI of average of 18.87 mm with standard deviation of 0.902 
mm in diameter. The results showed that both types of the ZnS particles have antibacterial 
effectiveness on S. aureus, however, whether the desired level of effectiveness was achieved was 
not yet determined and this is to be tested in the CFU analyses. 
Statistical analyses (see Appendix A.1) showed that the ZOI diameter data collected 
followed normal distributions and the two groups of data had equal variance, thus the 
corresponding Student’s t test was employed to test the difference in means of ZOI diameters 
between Comp A and Comp B treatment group. Test results showed that there was significant 
difference between the two treated groups and Comp B had better antibacterial properties than 
Comp A based on ZOI assays. 
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Figure 4.9: ZOI results for 50 mg ZnS Comp A treatments 
 
Figure 4.10: ZOI results for 50 mg ZnS Comp B treatments 
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4.4.4 In Vitro Biofilm Model CFU Analyses 
 
Based on the in vitro biofilm CFU assays, Figure 4.6 showed statistics of residual 
bacteria that were left on the biofilm based on 50, 25, 15 and 10 mg of ZnS Comp A treatments 
on an disk with area of diameter of 6 mm, and Figure 4.7 showed the statistics tested under the 
same condition for Comp B. Figure 4.6 and 4.7 also showed results for Untreated control disks 
and PEG disks, the statistics used were the same for these two groups. There were three samples 
under each treatment group. As the bacteria grow exponentially, all data were plotted in log 10 
scale. A minimum of 99.9% inhibition (3 log bacteria reduction) is usually required to prove the 
effectiveness of the antibacterial agents [45]. 
Statistical analyses (see Appendix A.2) showed that the original data collected through 
repeated measurements did not follow normal distribution, and a reduced model of linear 
mix-effect model was used to analyze the data as shown in Appendix A.2. In the new model, 
repeatedly measured data were averaged to represent the observation of each specific sample. 
Based on normality assumption and equal variance assumption, corresponding one-way ANOVA 
test was used to test difference in means between groups, the conclusions showed that: 1) both 
Comp A and Comp B when mixed with PEG can completely inhibit bacterial biofilm formation 
at 15 mg or higher level of treatment. 2) at 10 mg level of treatment, both Comp A and Comp B 
when mixed with PEG could reach 3 log reduction of bacteria counts, which met requirements 
desired level of antibacterial effectiveness. 3) Comp B showed better antibacterial effectiveness 
than Comp A. 4) PEG has no antibacterial effect. 
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Figure 4.11: Log transformed CFU statistics for control and Comp A treatments 
 
Figure 4.12: Log transformed CFU statistics for control and Comp B treatments 
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4.4.5 CLSM Analysis 
 
CLSM analysis is the qualitative result of antibacterial effectiveness for different 
compounds. Figure 4.8 showed the results of CLSM analysis of bacteria on the biofilms after 
being treated with ZnS Comp A. Complying with the statistics from in vitro biofilm model 
analysis, the untreated disks and disks with PEG controls showed that the biofilms had well 
developed. Due to higher concentration of ZnS, the disks with levels of 50, 25 and 15 mg ZnS 
treatments showed good antibacterial effectiveness, as there was no green fluorescence left under 
these treatment levels, indicating the biofilm forming bacteria strains were all eradicated. 
However, at the 10 mg level, there were obvious bacteria strains left, which indicated that the 
bacteria were not completely eradicated due to lower concentration of ZnS. The CLSM results 
aligned with the in vitro biofilm model quantitative analyses. 
Figure 4.9 showed the results of CLSM for biofilms treated with ZnS Comp B. In this 
case, the results were the same under higher dosages as 50, 25 and 15 mg treatments with Comp 
A, all biofilms were eradicated. However, the result under dosage of 10 mg Comp B showed 
different result with same amount of dosage of Comp A, this difference in antibacterial 
properties was due to the dosage differences between treatments, which is also confirmed by 
other studies using ZnO or Ag [16, 46]. In the meantime, due to effect of cryomilling, Comp B 
showed better eradication of biofilms than Comp A under 10 mg level.  
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Figure 4.13: CLSM results of controls and treatments of Comp A 
 
Figure 4.14: CLSM results of controls and treatments of Comp B 
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4.5 Discussion 
 
The results showed that the ZnS particles possess antibacterial properties both before and 
after cryomilling. The antibacterial properties may be due to two different mechanisms: first is 
the release of zinc ions, which plays a major roles in killing the bacteria, and secondly, the direct 
deposition of the nanoparticles may also have an impact on cell death [47-49]. However, we see 
that the Comp B, which was the cryomilled sample, showed better antibacterial effectiveness 
than Comp A, as the decrease in particle size, which resulted in increase in surface to volume 
ratio, has increased the ZnS antibacterial effectiveness. It has been proven that the smaller the 
particle size, the better antibacterial properties the particles have due to more soluble zinc ions 
released from the particles [47]. 
Besides particle size changes, cryomilling might have introduced difference in terms of 
lattice constant. As sphalerite has cubic crystal structure with lattice constant c of 0.5404 nm 
[50], mechanical milling will result in a change in the crystal structure. Past research has shown 
that milling will result in slightly higher c values [51], and a lattice relaxation occurred along the 
axis for zinc oxide [52]. The increased c value has significant effect on the amount of H2O2 
generated from the surface of the particles, which in turn helps the inhibition of bacterial growth 
[26, 53]. This is another possible reason that explains the better antibacterial activity of Comp B. 
One possible reason for the difference between chemically synthesized and 
biosynthesized ZnS in terms of antibacterial properties, was the chemical composition. The 
chemical synthesis produced ZnS particles with white color, while the biosynthesis ZnS 
possessed a deep purple color. Although XRD profiles showed that the bulk compositions of 
both types of particles were ZnS, the XRD technique has the limitation that the presence of other 
phases in very low concentration and/or amorphous phases cannot be detected [54]. Studies 
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showed that the biosynthesized ZnS nanoparticles are usually bound to proteins [24, 55]. Other 
studies also showed similar results for biosynthesized silver nanoparticles [56, 57]. These 
proteins are either released by dead cells or generated by live cells [55], the antibacterial 
properties of these proteins are unknown. However, for chemically synthesized ZnS, the particles 
might be encapsulated by non-toxic white polymer PVP [58] based on one-pot colloidal 
synthesis [22]. So the properties of proteins and their organization might be the reason that 
caused difference in color and the difference in antibacterial properties between the chemical and 
biological synthesis of ZnS. However, the concentration of proteins is low [55], and the 
identification of the actual types of proteins attached to the ZnS needs further investigation. 
The ZnS in this study was mixed with PEG ointment, which served as delivery method, 
however, different ways of drug delivery may also be taken into consideration for future 
direction of this project. As 10 mg of ZnS was mixed in 100 mg of PEG, the concentration is 
9.09% wt%. One study used Sidr and Manuka honey as topical antibacterial agent to treat S. 
aureus biofilm, the concentration had to be 50% in order to be effective [59], another study used 
Next Science Gel mixed with PEG to treat S. aureus biofilm, which had concentration of 0.36% 
[31], one study used silver containing nanocomposites AgNO3 mixed with gelatin which 
contained 2.5% of the materials to apply on S. aureus biofilm [60]. Commercially available 
silver nitrate cream for wound healing contains 10% of silver nitrate, hydrogen peroxide cream 
has 1% of H2O2, silver sulfadiazine cream contains 1% active ingredient, nitrofurazone cream 
contains 0.2% of the material [61]. By comparing with other topical antibacterial agents, the ZnS 
treatment in this study showed relatively high concentration, which requires more study for 
decreasing the concentration while retaining the antibacterial properties. 
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4.6 Conclusions 
 
A novel approach of antibacterial agent for burn wound treatment has been introduced. 
The ZnS particles were biologically, reproducibly and economically synthesized with anaerobic 
sulfate reducing bacteria Thermoanaerobacter species. Smaller sized ZnS particles were 
produced by grinding original biologically synthesized ZnS under cryogenic environment for 56 
min. Both types of ZnS have been proven to be statistically significant demonstrating ZnS 
effectiveness against common burn wound infection bacteria Staphylococcus aureus and its 
biofilm. Cryomilling decreased the original particle sizes, thus increased the surface to volume 
ratio. ZOI results also showed that plates treated with cryomilled ZnS samples have larger 
inhibition areas. Both types of ZnS, when mixed with PEG ointment showed 8 log reduction on 
bacteria strains left on the biofilm at level of 50, 25 and 15 mg. However, at 10 mg level, original 
ZnS particles mixed with PEG ointment showed approximately 3 log reduction on bacteria 
strains, while an approximately 7 log reduction on bacteria strains for cryomilled ZnS. Overall 
ZnS particles have been proven to possess antibacterial effectiveness against Staphylococcus 
aureus and cryomilling imposes a positive effect on ZnS antibacterial effectiveness. 
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CHAPTER 5. 
GENERAL CONCLUSIONS 
 
5.1 Conclusions 
 
This thesis has summarized literature on burn wound healing and treatments, as well as 
information on ZnS properties and its synthesis. The major part of this thesis demonstrates the 
study of ZnS effectiveness as antibacterial substance for burn wound healing. Based on this 
study, a novel approach of antibacterial agent for burn wound treatment has been introduced. The 
ZnS particles (Comp A) were biologically, reproducibly and economically synthesized with 
anaerobic metal-reducing Thermoanaerobacter species. Cryomilled ZnS particles (Comp B) 
were successfully produced by grinding original biologically synthesized ZnS particles under 
cryogenic environment for 56 min. The conventional chemical one-pot colloidal synthesis was 
also conducted, both as-synthesized ZnS (Comp C) and further cryomilled ZnS (Comp D) were 
evaluated. In comparison, Comp C did not show antibacterial properties against S. aureus, but 
cryomilled sample Comp D showed very good antibacterial properties. Both Comp A and Comp 
B have been proven to have significant effectiveness against common burn wound infection 
bacteria S. aureus. Cryomilling decreased the original particle sizes by order of about 3000, 
which has significantly increased the surface to volume ratio. ZOI results have also proved that 
Comp B has larger inhibition areas than Comp A. Both Comp A and B, when mixed with PEG 
ointment showed 8 log reduction on bacteria strains left on the biofilm at level of 50, 25 and 15 
mg when applied on area of diameter of 6 mm. However, the ZnS particles mixed with PEG 
ointment showed approximately 3.5 log reduction on bacteria strains at level of 10 mg for Comp 
A, while a 7 log reduction on bacteria strains for Comp B. Overall ZnS particles have been 
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proven to possess antibacterial effectiveness and cryomilling imposes an positive effect on ZnS 
antibacterial effectiveness. 
 
5.2 Review of Contributions 
ZnS possess antibacterial properties against S. aureus and cryomilling as a fabrication 
process has improved the ZnS antibacterial effectiveness. In a world of infections with more 
drug resistance, the new drug of ZnS can have high potential of application. 
 
5.3 Future Perspectives 
 
In order to further understand the characteristics antibacterial properties of the material: 
1) In vivo studies are necessary to examine the effectiveness of ZnS on animals and humans with 
S. aureus infections. 2) As this study has proven the effectiveness of ZnS only on gram-positive 
bacteria S. aureus, more studies on other microorganisms like gram-negative bacteria and fungi 
are in order. 3) Further investigation on cryomilling is also necessary to study ZnS antibacterial 
effectiveness based on gradually increased cryomilling time. 4) Lastly, a study identifying how 
surface composition could make a difference in terms of antibacterial properties needs to be 
developed. 
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APPENDIX A. 
STATISTICAL ANALYSES OF ZNS ANTIBACTERIAL TESTS 
 
 
Appendix A summarizes all the details of statistical analyses for section 4.4.3 and 4.4.4 in 
terms of derivations, assumptions, validations and tests. A.1 provides detailed explanation of 
statistical analyses for ZOI assay, and A.2 provides detailed explanation of statistical analyses 
for in vitro biofilm model CFU analyses. 
 
A.1 Statistical analyses for ZOI assay 
  
There were three samples in each treatment group, they were all tested under the same 
condition within each group, so the diameters of ZOI in each treatment group were expected to 
have the same distribution. By following the ZOI assay protocol, the ZnS treatments were placed 
on the bacterial lawn at least 24 mm (center to center) away from each other [185]. Also, 
according to Figures 4.4 and 4.5, there was no overlap between each of the two inhibition zones, 
so that each sample was expected to be independent from the other, and the assumption was 
made that the observed diameters of the inhibition zones under each treatment were independent 
and identically distributed random variables, they were denoted as YAi and YBi (i = 1, 2, 3). 
Figure A.1 showed the distributions of the data points, and their corresponding normal quantile 
plots of the two treatment groups. For small sample size, Shapiro-Wilk W test has higher power 
by comparison to other normality test [192], thus is usually used to test normality of the data, and 
the corresponding null hypothesis was that the samples were from normally distributed 
population. The test using JMP software revealed p values of 0.7470 and 0.8777 for Comp A and 
Comp B ZOI assay data respectively (See Appendix B.1 for calculation procedure for 
Shapiro-Wilk W test), which failed to reject the null hypothesis. 
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In this test, the sample size was very small (n = 3), the power was very low, usually not 
higher than 0.2 given the sample size [192, 193]. However, according to the data collected in 
database of European Society of Clinical Microbiology and Infectious Diseases, the distributions 
of ZOI diameters from antibacterial tests on S. aureus using antibiotics are basically normal 
[194], thus researchers usually assume that the distributions of ZOI diameters are normal 
[195-197]. Given that the Shapiro-Wilk W tests revealed the same results, the corresponding 
Student’s t tests can be used to statistically evaluate the difference in means as Student’s t test 
assumes normality of the data.  
 
Figure A.1: ZOI statistics and normal quantile plots 
 
In order to compare difference between ZOI results under two different treatments, 
assumption of equal variances is needed to perform a Student’s t test. A two-sided F-test at 0.95 
confidence level was performed to check the equal variance of the two sample groups with the 
null hypothesis being that the variances of the two groups were equal. The test showed the p 
value 0.6917 (See Appendix B.2 for calculation procedures for two-sided F test). As p value was 
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larger than the designated Type I error rate 0.05, the null hypothesis was not rejected, thus 
conclusion was made that the variances were equal between the two groups. Still, the sample size 
was very small, there might not be enough power for the test, however, equal variance is usually 
assumed and the Student’s t-test is used [195, 198]. 
In order to test the difference between the means of ZOI diameters under Comp A and 
Comp B treatments, a right-tail Student’s t-test assuming equal variance was performed at 0.95 
confidence level with pooled variance. Let 𝜇𝐴 and 𝜇𝐵 denote the true means of diameter of 
ZOI under 50 mg treatment of Comp A and Comp B respectively. In antibacterial ZOI test, the 
larger ZOI diameter indicates better antibacterial properties [185]. Thus the test was based on the 
following null and alternative hypotheses: 
𝐻0: 𝜇𝐴 = 𝜇𝐵                                                                      (A. 1) 
𝐻𝑎: 𝜇𝐴 < 𝜇𝐵                                                                      (A. 2) 
The result showed a p value of 0.0002 (See appendix B.3 for calculation procedures of 
Student’s t test), which was smaller than the designated Type I error rate 0.05, thus the null 
hypothesis was rejected and this concluded that 50 mg Comp B treatment had significantly better 
antibacterial properties than 50 mg Comp A treatment based on ZOI assays. 
In conclusion, based on the assumptions of normal distribution and equal variance, the 
Student’s t-test showed that there was significant difference between the two treated groups and 
Comp B had better antibacterial properties than Comp A based on ZOI assays. 
 
A.2 Statistical analyses for In vitro biofilm model CFU analyses 
 
As stated in Section 4.4.4, requirement of minimum of 99.9% of bacteria reduction needs 
to be reached in order to be considered as effective [199], which can be expressed in Equation 
A.3, where 𝜇𝑏𝑒𝑓𝑜𝑟𝑒 denotes true mean CFU value left on the disk before treatment and 𝜇𝑎𝑓𝑡𝑒𝑟 
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denotes true mean CFU value left on the disk after treatment. Equations A.4 and A.5 were the 
arithmetic derivations from Equation A.3. 
𝜇𝑏𝑒𝑓𝑜𝑟𝑒 𝜇𝑎𝑓𝑡𝑒𝑟⁄ > 1000                                                            (A. 3) 
lg(𝜇𝑏𝑒𝑓𝑜𝑟𝑒 𝜇𝑎𝑓𝑡𝑒𝑟⁄ ) > lg(1000)                                                    (A. 4) 
lg(𝜇𝑏𝑒𝑓𝑜𝑟𝑒) − lg(𝜇𝑎𝑓𝑡𝑒𝑟) > 3                                                      (A. 5) 
 Equation A.3 and Equation A.5 are mathematically equivalent, in the 10 log 
transformed data, requirement of a minimum of 99.9% reduction (3 log reduction) is equivalent 
to the difference of true means being larger than 3 between before and after treatment groups. 
Based on the calculations, the log transformed raw data can be used instead of raw data. For the 
convenience of analyses and notation, the transformed data were referred as original data here 
and after while the non-transformed data were referred as raw data here and after. 
All groups were tested independently, and due to the nature of the experiment each disk 
was washed and biofilm destroyed in order to count the CFU. There was no paring between each 
two groups. PEG was used as carrier material to immobilize the ZnS particles on the disks. PEG 
had nonmeasureable effectiveness [182]. Also, as ZnS is not soluble in nature, while PEG is 
hydrophilic with low melting point (4 – 8 °C) [200], mixing ZnS with PEG promoted an even 
diffusion of metal ions [182, 201]. However, studies have reported that PEG as a carrier material, 
when mixed with ZnO or Ag nanoparticles, does not show enhancement of antibacterial 
properties than testing the nanoparticles alone in suspension state, due to the reason that when 
these particles are in suspension, the antibacterial substances, like metal ions, can diffuse evenly 
without promotion of PEG [202-204]. As ZnS mixed with PEG as a whole was considered as the 
treatment, in this experiment, the antibacterial properties were reported on ZnS mixed with PEG, 
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but the discussion of mechanisms that cause the difference in antibacterial properties was based 
on differences between Comp A and Comp B. 
Under 15 mg to 50 mg levels of Comp A and Comp B treatments, all bacteria were 
completely eradicated. The raw data of CFU values for these samples were all 0, and there were 
no variances associated with these groups. This showed that 15 mg to 50 mg of ZnS Comp A and 
Comp B were able to completely inhibit biofilm formation due to higher drug concentrations 
[205]. However, the 10 mg treatment groups for both Comp A and Comp B, untreated groups 
and PEG treated groups had bacteria strains left on the disks due to insufficient ZnS 
concentration, statistical analyses were needed to evaluate the differences between these groups. 
For the convenience of analyses, the untreated group was referred as the “Control” group, 
the PEG group as Treatment 1, the 10 mg Comp A group as Treatment 2, and the 10 mg Comp B 
group as Treatment 3 here and after. 
Each treatment group had three samples, there was variance associated between samples. 
Each CFU measurement from each sample was repeated three times to get more accurate data, 
there was also variance associated between readings. Considering variance between samples and 
variance within measurements, linear mixed effect model is appropriate to fit this situation as it 
allows combination of regression methods while accounting for the repeated measures of the 
data [206, 207]. A linear mixed effect model can be expressed using the equation A.6 [208]: 
𝒚 = 𝑿𝜷 + 𝒁𝒖 + 𝝐                                                                (A. 6) 
In equation A.6, y is a known vector of observations, with 𝐸(𝒚) = 𝑿𝜷, 𝜷 is an 
unknown vector of fixed effects. As each treatment has only one level, thus 𝜷 contains only 
main effects of different treatments, and statistical inferences were made through comparing 
contrasts of main effects. u is an unknown vector of random effects, with mean E(u) = 0 and 
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variance-covariance matrix var(u) = G. In this experiment, there was only one random variable 
for each observation in vector u which denotes the variance between samples in the same 
treatment, so that there was no covariance in this matrix. 𝝐 is unknown vector of random errors, 
with mean E(𝝐) = 0 and variance var(𝝐) = R. Assumption was made that cov(𝒖, 𝝐) = 0, as 
variance between samples and variance within measurements are usually assumed to be 
independent from each other [208]. This equation can be expressed as equation A.7 to address 
this experiment design for each single observation: 
𝑦𝑖𝑗𝑘 = 𝜇 + 𝛼𝑖 + 𝑢𝑖𝑗 + 𝑒𝑖𝑗𝑘                                                      (A. 7) 
where i = 1 … 4 (4 groups), j = 1 … 3 (3 samples in each group), k = 1 … 3 (3 repeated 
measurements for each sample). Initially assumptions associated with this model are made that 
𝑢𝑖𝑗  are i.i.d. and follow 𝐷1(0, 𝜎𝑢
2)  distribution. Also 𝑒𝑖𝑗𝑘  are i.i.d. and follow 𝐷2(0, 𝜎𝑒
2) 
distribution, 𝑢𝑖𝑗  and 𝑒𝑖𝑗𝑘  are independent from each other, thus 𝑦𝑖𝑗𝑘  are i.i.d. and follow 
𝐷3(𝜇 + 𝛼𝑖, 𝜎𝑢
2 + 𝜎𝑒
2) distribution. Di stands for a certain distribution (normal or otherwise). 
To apply ANOVA analyses requires normality of the data, so that  𝑢𝑖𝑗 and 𝑒𝑖𝑗𝑘 need to 
follow normal distributions, it true, 𝑦𝑖𝑗𝑘 should also follow normal distribution. In order to test 
whether assumption 𝑦𝑖𝑗𝑘~𝑁(𝜇 + 𝛼𝑖, 𝜎𝑢
2 + 𝜎𝑒
2) could be used, Shapiro-Wilk W test at 0.95 
confidence level was employed to test the normality of the data. The null hypothesis for this test 
was that the data were sampled from normally distributed population. As 𝛼𝑖 are fixed effect, 
and are different between treatments, the normality was tested separately for data collected under 
each treatment group. Figure A.2 summarized the distributions of all observations and their 
corresponding box plots and normal quantile plots. Based on JMP analysis results, Table A.1 
summarized the p values for each group: 
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Figure A.2: Observed CFU statistics for different treatments with normal quantile plots and box 
plots 
 
Table A.1: Normality tests results for all observations in different treatment groups 
Groups Control Treatment 1 Treatment 2 Treatment 3 
p value 0.0065 0.0038 0.2570 0.1642 
 
As p values for Control and Treatment 1 groups were smaller than the designated Type I 
error rate 0.05, the null hypotheses that data from Control and Treatment 1 groups were sampled 
from normally distributed populations were rejected. However, for Treatment 2 and 3 groups, 
they had p values higher than the designated Type I error rate 0.05, the null hypotheses were not 
rejected. 
The typical methods of dealing with non-normal data for the convenience of analysis is 
applying transformations [209]. Different transformations were used in attempt to obtain normal 
distribution for Control and Treatment 1 groups, and the normality of the transformed data were 
also evaluated using Shapiro-Wilk W tests at 0.95 confidence level. Based on the results, the 
common transformations were unable to transform the data of Control and Treatment 1 into 
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normally distributed data as their corresponding p values were all still below the designated Type 
I error rate 0.05, and the null hypotheses were rejected. Table A.2 summarized the p values for 
each group after transformations. As a result, the transformations were not employed and the 
analyses would still be based on original data. 
Table A.2: Normality tests results for different transformation methods 
Transformation Groups Control Treatment 1 Treatment 2 Treatment 3 
Log p value 0.0063 0.0028 0.2509 0.2162 
Square Root p value 0.0064 0.0032 0.2549 0.1901 
Reciprocal p value 0.0061 0.0020 0.2375 0.2635 
Box-Cox P value 0.0060 0.0050 0.2183 0.2264 
 
As the test results indicated, the assumption that 𝑦𝑖𝑗𝑘~𝑁(𝜇 + 𝛼𝑖, 𝜎𝑢
2 + 𝜎𝑒
2) could not be 
used as normality was not proven. Hence derivations from equation A.7 were shown below to 
reduce the original model (K stands for number of repetition and is equal to 3): 
𝑦
𝑖𝑗∙
=
1
𝐾
∑ 𝑦𝑖𝑗𝑘
𝐾
𝑘=1
=
1
𝐾
∑(𝜇 + 𝛼𝑖 + 𝑢𝑖𝑗 + 𝑒𝑖𝑗𝑘)
𝐾
𝑘=1
= 𝜇 + 𝛼𝑖 + 𝑢𝑖𝑗 +
1
𝐾
∑ 𝑒𝑖𝑗𝑘
𝐾
𝑘=1
       (A. 8) 
Let 𝜃𝑖𝑗 = 𝑢𝑖𝑗 +
1
𝐾
∑ 𝑒𝑖𝑗𝑘
𝐾
𝑘=1 , the equation A.8 can be rewritten as: 
𝑦
𝑖𝑗∙
= 𝜇 + 𝛼𝑖 + 𝜃𝑖𝑗                                                               (A. 9) 
As 𝑢𝑖𝑗  are i.i.d. and follow 𝐷1(0, 𝜎𝑢
2) distribution, also 𝑒𝑖𝑗𝑘  are i.i.d. and follow 
𝐷2(0, 𝜎𝑒
2) distribution, 𝑢𝑖𝑗 and 𝑒𝑖𝑗𝑘 were independent, so that: 
var (𝑦
𝑖𝑗∙
) = var(𝜃𝑖𝑗) = var(𝑢𝑖𝑗) + var (
1
𝐾
∑ 𝑒𝑖𝑗𝑘
𝐾
𝑘=1
) =  𝜎𝑢
2 +
1
𝐾2
∙ 𝐾𝜎𝑒
2 = 𝜎𝑢
2 + 𝜎𝑒
2 𝐾⁄   (A. 10) 
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So 𝑦
𝑖𝑗∙
 were also i.i.d. and follow 𝐷4(𝜇 + 𝛼𝑖, 𝜎𝑢
2 + 𝜎𝑒
2 𝐾⁄ ) distribution. In this case, the 
linear mixed-effect model has been reduced to a simple linear model, and the new observations 
became the averaged repeated measurements in each sample. As ANOVA analysis based on this 
model also requires normality of the data, the Shapiro-Wilk W tests were performed to check 
normality of averaged observations of each sample. 
Figure A.3 showed the distributions of the original data for the reduced model and their 
corresponding normal quantile plots. 
 
Figure A.3: Averaged CFU statistics for different treatments and normal quantile plots 
 
Based on the normal quantile plots, log(CFU) data for all 4 groups all scattered 
approximately on a straight line. In order to statistically test the normality of the data, the 
Shapiro-Wilk W test for each treatment group at 0.95 confidence level was performed. The null 
hypothesis for this test was that the data were sampled from normally distributed population. 
Based on JMP analysis results, Table A.3 summarized the p values of normality test for each 
group: 
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Table A.3: Normality tests results for averaged statistics for different treatment groups 
Groups Control Treatment 1 Treatment 2 Treatment 3 
p value 0.8877 0.4256 0.3502 0.0789 
 
Based on the test results, all p values were greater than the designated Type I error rate 
0.05, so the null hypotheses that these data were sampled from normally distributed populations 
were not rejected. But it is important to see that in this experiment, the sample size was very 
small, which might not give enough power for the test, in another word, the Type II error rate 
might be very high. Type II error by definition means the failure to reject a false null hypothesis 
[209], which in this Shapiro-Wilk W test means the original data actually did not follow normal 
distribution. However, many researchers have studied the distribution of CFU data for 
microorganisms, as bacteria grow and die exponentially, when logarithms are used, a log-normal 
distribution of micro-organisms is assumed to be approximately correct, and the logarithms of 
data can be used to obtain mean log count and standard deviation to describe the distribution 
[210-213]. Thus the null hypotheses were accepted and the assumptions that the four different 
groups were sampled from normally distributed populations were used here and after. Thus 
𝑦
𝑖𝑗∙
~𝑁(𝜇 + 𝛼𝑖 , 𝜎𝑢
2 + 𝜎𝑒
2 𝐾⁄  ) were assumed, and the reduced model shown in equation A.9 
could be used for further analysis. 
First the test of equal variance needs to be conducted for the ANOVA analysis. In order 
to test among four groups, Levene’s test, Hartley’s test or Bartlett’s test can be employed. 
However, among them, Levene’s test is robust and less sensitive to departure from normality 
[214], and was chosen to test equal variance with the null hypothesis that the four sample groups 
had equal variance. Using JMP software, the test revealed a p value of 0.1072 (See Appendix B.4 
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for calculation procedures for Levene’s test), which is higher than the designated Type I error 
rate 0.05, so the null hypothesis was not rejected, and conclusion could be made that the four 
groups had equal variance. 
As stated above, the data collected in each group followed normal distribution, and equal 
variance was proven across the groups. One-way ANOVA could be performed to check if there 
was significant difference between the treatment groups with null hypothesis being that there 
was no difference between the means of each group (See Appendix B.5 for calculation 
procedures for ANOVA). Table A.4 showed the results for ANOVA. 
Table A.4: ANOVA analysis table 
Source d.f. Sum of Squares Mean Squares F p 
Treatment 3 86.341466 28.7805 667.9085 < 0.0001 
Error 8 0.344724 0.0431   
Total 11 86.686190    
 
The result revealed a p value of < 0.0001, which is smaller than the designated Type I 
error rate 0.05, so the null hypothesis was rejected, thus there were significant differences 
between groups. 
PEG was used to carry the ZnS for burn wound healing, whether PEG has antibacterial 
properties needed to be confirmed, thus contrast between Control and Treatment 1 was tested. To 
check if Comp A and Comp B could reach desired antibacterial effectiveness (3 log reduction), 
comparisons needed to be made between Control group and Treatment 2 and 3 groups 
respectively. Lastly, comparison needed to be made between Treatment 2 and 3 groups to 
determine if cryomilling had impact on antibacterial effectiveness. So altogether there were four 
multiple comparisons needed to be made to establish the antibacterial effectiveness of ZnS 
mixed with PEG. However, multiple comparisons will increase the Type I error rate if we 
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maintain 0.05 Type I error rate for each individual test, thus the Bonferroni correction could be 
used to control the family wise error rate to at most 0.05 [209, 215]. There were 4 different 
comparisons, thus the individual error rate is 0.0125 as calculated in equation A.11 and this 
corrected Type I error rate would be used for the four multiple comparisons mentioned above. 
𝛼𝐼 =
𝛼𝐸
𝑚
=
0.05
4
= 0.0125                                                        (A. 11) 
First the difference between Control group and Treatment 1 group was compared. The 
null hypothesis was that the two groups had no difference in terms of group means, which can be 
shown in the following form (Let 𝜇𝑐𝑜𝑛𝑡𝑟𝑜𝑙 and 𝜇𝑃𝐸𝐺 denote the true means of log(CFU) values 
under Untreated and PEG groups respectively): 
𝐻0: 𝜇𝑐𝑜𝑛𝑡𝑟𝑜𝑙 = 𝜇𝑃𝐸𝐺                                                                (A. 12) 
𝐻𝑎: 𝜇𝑐𝑜𝑛𝑡𝑟𝑜𝑙 ≠ 𝜇𝑃𝐸𝐺                                                              (A. 13) 
Using two-sided Student’s t test, it revealed a p value of 0.3892, which was larger than 
the corrected Type I error rate, so the null hypothesis was not rejected, thus conclusion could be 
made that the PEG had no antibacterial properties. 
Secondly the difference between Control group and Treatment 2 groups was compared. 
In order to test if 10 Comp A with PEG has reached desired antibacterial level (3 log reduction), 
the null hypothesis can be expressed as follows (Let 𝜇𝑃𝐸𝐺 and 𝜇𝐴 denote the true means of 
log(CFU) values under Control and 10 mg Comp A groups respectively): 
𝐻0: 𝜇𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝜇𝐴 = 3                                                         (A. 14) 
𝐻𝑎: 𝜇𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝜇𝐴 > 3                                                         (A. 15) 
Using right-tailed Student’s t test, it revealed a p value of 0.0032, which is smaller than 
the corrected Type I error rate 0.0125, so the null hypothesis was rejected, thus conclusion could 
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be made that 10 mg Comp A with PEG has reached desired antibacterial effectiveness of 3 log 
reduction. 
Using the same procedure, the difference between Control and Treatment 3 groups was 
tested. The right-tailed Student’s t test revealed a p value of < 0.0001, which is also smaller than 
the corrected Type I error rate 0.0125, so the null hypothesis was rejected. Thus the conclusion 
could be made that 10 mg Comp B with PEG has also reached desired antibacterial effectiveness 
of 3 log reduction. 
In order to approximately determine the actual antibacterial effectiveness, the subtraction 
of means between groups is usually used to measure the log reduction [216-218]. For Control 
group, the mean value for the original data was 8.1522, while the Treatment 2 group had an 
average value of 4.3067. The subtraction of these two value yielded a value of 3.8455 log 
reduction, which is equivalent to 99.98573% reduction of bacteria. 
Treatment 3 group had an average value of 1.7619. The subtraction between this value 
and Control group yielded a value of 6.3903 log reduction, which is equivalent to 99.99996% 
reduction of bacteria. 
So far the statistical analyses have proven that 10 mg of treatments of both Comp A and 
Comp B could both reach a desired level of antibacterial effectiveness, and then difference in 
antibacterial effectiveness of Comp A and Comp B themselves needed to be evaluated. Let 𝜇𝐴 
and 𝜇𝐵 denote the true means of log(CFU) values under Treatment 2 and 3 respectively, as 
fewer CFU counts mean better antibacterial effectiveness, the test was based on the following 
null and alternative hypotheses: 
𝐻0: 𝜇𝐴 = 𝜇𝐵                                                                 (A. 16) 
𝐻𝑎: 𝜇𝐴 > 𝜇𝐵                                                                 (A. 17) 
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Using right-tailed Student’s t test, the analysis revealed a p value of 0.0001, which was 
smaller than the corrected Type I error rate 0.0125, thus the null hypothesis was rejected and this 
concluded that Comp B had significantly better antibacterial properties than Comp A. This result 
also matched with the ZOI result as stated in section 4.4.3. 
Based on the analyses above, the following conclusions could be drawn: 1) both Comp A 
and Comp B when mixed with PEG can completely inhibit bacterial biofilm formation at 15 mg 
or higher level of treatment. 2) at 10 mg level of treatment, both Comp A and Comp B when 
mixed with PEG could reach desired level of antibacterial effectiveness. 3) Comp B showed 
better antibacterial effectiveness than Comp A. 4) PEG has no antibacterial effect. 
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APPENDIX B. 
ALGORITHMS FOR RELATED STATISTICAL TESTS 
 
This appendix is used to provide support information of calculation procedures for all 
statistical tests involved in Appendix A. 
 
B.1 Shapiro-Wilk W Normality Test Calculations 
 
Shapiro-Wilk W test is used for test normality of the data set with null hypothesis being 
that the observed data follow normal distribution. The test statistic is calculated using equation 
B.1 [219]. 
𝑊𝑡 =
(∑ 𝑎𝑖𝑥(𝑖)
𝑛
𝑖=1 )
2
∑ (𝑥𝑖 − ?̅?)2
𝑛
𝑖=1
                                                            (B. 1) 
First we sort the data in ascending order, in this equation, 𝑥(𝑖) is the i
th
 ordered statistic 
of the entire data set, ?̅? is the mean of all statistics. 𝑎𝑖 comes from a data set as shown in 
equation B.2: 
(𝑎1, ⋯ , 𝑎𝑛) =
𝒎T𝑽−1
√𝒎T𝑽−1𝑽−1𝒎
                                               (B. 2) 
In B.2, m is defined as B.3: 
𝒎 = (𝑚1, ⋯ , 𝑚𝑛)
T                                                          (B. 3) 
 In B.3, mi are the expected values of the ordered statistics of i.i.d. random variables sampled 
from the standard normal distribution, and V from equation B.2 is the covariance matrix of the 
ordered statistics. 
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Test statistic 𝑊𝑡 as well as sample size will be used to look up Shapiro-Wilk tables to 
find the matching W value, and the corresponding p value is used to compare with predefined 
Type I error rate 0.05. 
 
B.2 Two-sided F Test Calculations 
 
Assuming normality of the data set, two-sided F test can be used to test equal variance of 
two data sets with null hypothesis being there is no difference in variance between two groups. 
The test statistic is shown as equation B.4 (null hypothesis being variances are equal, thus 
𝜎1
2 = 𝜎2
2) [209]: 
𝐹𝑡 =
𝑠1
2 𝜎1
2⁄
𝑠2
2 𝜎2
2⁄
=
𝑠1
2
𝑠2
2                                                            (B. 4) 
Test statistic 𝐹𝑡 follows F distribution with 𝑑𝑓1 = 𝑛1 − 1, and  𝑑𝑓2 = 𝑛2 − 1, where 
𝑛1 and 𝑛2 are the sample sizes for two data sets. The more 𝐹𝑡 statistic deviates from 1, the 
stronger evidence that the variances are not equal. The test statistic 𝐹𝑡 and two df’s are used to 
look up in F distribution table to find matching F value, and the corresponding p value is the 
possibility of F value greater than 𝐹𝑡, this value is used to compare with predefined Type I error 
rate 0.05. 
 
B.3 Student’s t Test Calculations 
 
Assuming normality and equal variance, the Student’s t test can be used to test the 
difference in means for two data sets with null hypothesis being there is no difference in means 
between two groups. The test statistic is shown as equation B.5 [209]: 
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𝑡𝑡 =
𝑍
𝑠 √𝑛⁄
=
?̅?1 − ?̅?2
𝑠𝑋1𝑋2 √𝑛⁄
                                                       (B. 5) 
In equation B.5, ?̅?1 and ?̅?2 are the means of the two data sets, 𝑠𝑋1𝑋2 is the pooled 
standard deviation as shown in equation B.6: 
𝑠𝑋1𝑋2 = √𝑠1
2 + 𝑠2
2                                                            (B. 6) 
In equation B.6, 𝑠1
2 and 𝑠2
2 are the variances of the two data sets. 
Test statistic 𝑡𝑡 follows t distribution with 𝑑𝑓 = 𝑛1 + 𝑛2 − 2. For left sided Student’s t 
test, −𝑡𝑡 and df are used to look up in the t distribution table to find matching t value, and the 
corresponding p value is the possibility of absolute value of actual difference can be larger than 
−𝑡𝑡, this value is used to compare with predefined Type I error rate 0.05. For right sided 
Student’s t test, 𝑡𝑡 and df are used to look up in the t distribution table to find matching t value, 
and the corresponding p value is the possibility of actual difference can be larger than 𝑡𝑡, this is 
used to compare with predefined Type I error rate 0.05. For two sided Student’s t test, the 
absolute value of 𝑡𝑡 and df are used to look up in the t distribution table to find matching t value, 
and the corresponding p value is the two times of possibility of actual difference being larger 
than absolute value of 𝑡𝑡, this value is compare with predefined Type I error rate 0.05. 
 
B.4 Levene’s F Test Calculations 
 
Levene’s test is an inferential statistic used to assess the equality of variances for two or 
more groups [220], with null hypothesis being there is no difference in variances between groups. 
The test statistic is shown as in equation B.7: 
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𝑊𝑡 =
(𝑁 − 𝑘)
(𝑘 − 1)
∑ 𝑁𝑖(𝑍𝑖· − 𝑍··)
2𝑘
𝑖=1
∑ ∑ (𝑍𝑖𝑗 − 𝑍𝑖·)
2𝑁𝑖
𝑗=1
𝑘
𝑖=1
                                         (B. 7) 
In equation B.7, k is the number of groups, N is the total number of samples, 𝑁𝑖 is the 
number of samples in i
th
 group, 𝑍𝑖𝑗 = |𝑌𝑖𝑗 − ?̅?𝑖·|, 𝑌𝑖𝑗 is the specific observation of that sample, 
and ?̅?𝑖· is the mean of all samples in i
th
 group. 𝑍·· and 𝑍𝑖· are shown in equations B.8 and B.9: 
𝑍·· =
1
𝑁
∑ ∑ 𝑍𝑖𝑗
𝑁𝑖
𝑗=1
𝑘
𝑖=1
                                                          (B. 8) 
𝑍𝑖· =
1
𝑁𝑖
∑ 𝑍𝑖𝑗
𝑁𝑖
𝑗=1
                                                             (B. 9) 
According to equations B.8 and B.9, 𝑍·· is the mean of all 𝑍𝑖𝑗, and 𝑍𝑖· is the mean for 
all 𝑍𝑖𝑗 for i
th
 group. 
Test statistic 𝑊𝑡  follows F distribution with 𝑑𝑓1 = 𝑘 − 1  and 𝑑𝑓2 = 𝑁 − 𝑘 , these 
parameters are used to look up F distribution table to find matching F value, and the 
corresponding p value is the possibility of F value greater than 𝑊𝑡, this value is used to compare 
with predefined Type I error rate 0.05. 
 
B.5 One way ANOVA Calculations 
 
One way ANOVA is used to compare differences in means between two or more groups, 
with null hypothesis being there is no difference between means for all groups. The test statistic 
is shown in equation B.10: 
𝐹𝑡 =
𝑀𝑆𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
𝑀𝑆𝑒𝑟𝑟𝑜𝑟
=
𝑆𝑆𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 (𝑘 − 1)⁄
𝑆𝑆𝑒𝑟𝑟𝑜𝑟 (𝑁 − 𝑘)⁄
                                   (B. 10) 
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In equation B.10, 𝑀𝑆𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡  is the mean square error resulted from treatments, 
𝑆𝑆𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡  is its corresponding sum of error. 𝑀𝑆𝑒𝑟𝑟𝑜𝑟  is the mean square error due to 
sampling error, 𝑆𝑆𝑒𝑟𝑟𝑜𝑟 is its corresponding sum of error. N is the total number of samples in 
the experiment, k is the total number of treatments. 𝑆𝑆𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 and 𝑆𝑆𝑒𝑟𝑟𝑜𝑟 can be expressed 
as equations B.11 and B.12: 
𝑆𝑆𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 = ∑ 𝑛𝑖(?̅?𝑖· − ?̅?··)
2
𝑘
𝑖=1
                                         (B. 11) 
𝑆𝑆𝑒𝑟𝑟𝑜𝑟 = ∑ (𝑛𝑖 − 1)𝑠𝑖
2
𝑘
𝑖=1
                                              (B. 12) 
In equations B.11 and B.12, ?̅?·· is the grand mean for all observations, ?̅?𝑖· is the mean of 
all observations in i
th
 group, 𝑛𝑖 is the number of observations in i
th
 group, 𝑠𝑖
2 is the variance of 
all samples in i
th
 group. 
Test statistic 𝐹𝑡  follows F distribution with  𝑑𝑓1 = 𝑘 − 1  and 𝑑𝑓2 = 𝑁 − 𝑘,  these 
parameters are used to look up F distribution table to find matching F value, and the 
corresponding p value is the possibility of F value greater than 𝐹𝑡, this value is used to compare 
with predefined Type I error rate 0.05. 
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APPENDIX C. 
IMMUNE REACTIONS OF ZNS TREATMENT 
 
This Appendix is used to discuss the immune reactions when ZnS is applied on the 
wound and possible danger of reducing the particle size to nanoscale. 
Burn results in open wounds, and ZnS particles, as foreign bodies, can trigger immune 
reactions by body’s immune system. Studies have shown that nanoparticles are able to penetrate 
the stratum corneum of the skin, typically through hair follicles [221], flexed [222] and broken 
skin [223], the broken skin will facilitate the penetration with large particles, followed by 
translocation of nanoparticles from skin into the lymphatic system [224] and eventually moved 
to lymphatic nodes [225]. Particles that are not able to be killed by macrophages will be 
translocated to the liver, spleen or kidneys. Renal clearance of nanoparticles has been reported, 
and the clearance time is positively related to particle size left in the kidneys, the larger the size, 
the longer the clearance takes [226, 227]. In the meantime, hepatic clearance represents another 
primary route of excretion for particles that do not undergo renal clearance, the liver provides 
critical function of catabolism and biliary excretion of blood-borne particles as well as serve as 
important site for eliminating foreign substances through phagocytosis [228]. 
However, decreasing the particle size may result in toxication, especially for particles 
within nanometer range [229], as nanoparticles have much higher surface to volume ratio, 
therefore more chemical molecules may attach to the surface, which would enhance its reactivity 
and result in increase of toxic effects [230, 231], and the smaller the particles, the higher toxic 
effect they may have [225]. Thus even if decreasing the particle size may result in better 
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antibacterial properties, it is important to note that the possible toxicity associated with the 
particle size.  
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APPENDIX D. 
HYDROGEN PEROXIDE QUANTIFICATION METHODS 
 
 
This appendix discusses the methods of quantifying amount of H2O2 generated by 
material processed through cryomilling as discussed in Section 4.5, which results in different 
lattice constants. 
The amount of H2O2 can be measured using UV-Visible Spectroscopy as H2O2 has an 
absorbance peak of 240 nm, and the concentration of H2O2 is positively correlated with intensity 
of the peak [232]. However, this is not a very sensitive method. Another frequently used method 
to measure the amount of H2O2 with higher sensitivity is through oxidation of ferric iron to its 
ferrous state, which will form a complex with the dye xylenol orange, resulting in an increase in 
absorbance of the solution at 550 nm [233]. This method is more sensitive and selective.   
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